Section |
Name |
Details |
24.01 |
Palivizumab IM Syringe Synagis® |
|
05.03.01 |
Abacavir Ziagen® |
|
05.03.01 |
Abacavir and Lamivudine Kivexa® |
Tablets |
05.03.01 |
Abacavir and Lamivudine and Zidovudine Trizivir® |
|
06.01.01.02 |
Abasaglar® Insulin glargine |
3mL pre-filled disposible pen (KwikPen®) 3mL cartridge
|
10.01.03 |
Abatacept |
Intravenous infusion
|
24.03 |
Abatacept IV Infusion |
|
02.09 |
Abciximab |
Injection |
04.10.01 |
Acamprosate |
Gastro-resistant tablets
Only in conjunction with specialist service |
06.01.02.03 |
Acarbose Glucobay® |
Tablets |
02.08.02 |
Acenocoumarol Sinthrome® |
Tablets |
02.08.02 |
Acenocoumarol Sinthrome® |
Tablets |
11.06 |
Acetazolamide Diamox® |
Tablets
Sustained release capsules
Injection
Ophthalmic specialist initiation only |
12.01.01 |
Acetic Acid 2% Earcalm ® |
Ear Spray |
11.08.02 |
Acetylcholine Chloride |
Intraocular irrigation |
05.03.02.01 |
Aciclovir |
Tablets
Suspension
Intravenous Infusion |
13.10.03 |
Aciclovir Zovirax® |
Cream |
13.05.02 |
Acitretin Neotigason® |
Capsules
Dermatology only |
03.01.02 |
Aclidinium Eklira Genuair® |
Inhaler 400 micrograms/dose
|
03.01.04 |
Aclidinium / Formoterol Duaklir® Genuair |
Combination LABA/LAMA inhaler
|
06.01.01.01 |
Actrapid® |
10ml vial |
01.05.03 |
Adalimumab Humira® |
|
01.05.03 |
Adalimumab Amgevita® |
|
10.01.03 |
Adalimumab Amgevita®) (BIOSIMILAR |
Subcutaneous Injection
|
10.01.03 |
Adalimumab Humira® |
Subcutaneous Injection
|
13.05.03 |
Adalimumab Humira® |
|
09.05.01.01 |
Adcal® |
Chewable tablets |
05.03.03.01 |
Adefovir Dipivoxil Hepsera® |
|
02.03.02 |
Adenosine Adenocor® |
Injection
Infusion |
02.07.03 |
Adrenaline / Epinephrine |
Injection |
03.04.03 |
Adrenaline / epinephrine |
Injection (IM/SC)
Injection (IV) Extreme caution
Intravenous adrenaline should only be given by those experienced in its use, in a setting where patients can be carefully monitored. See BNF for more information. Intramuscular injection for self-administration (auto-injector) (EpiPen®, Jext®)
It is advisable to prescribe adrenaline auto-injector by brand to avoid confusion.
|
11.08.02 |
Aflibercept Eylea® |
Intravitreal injection
Ophthalmic consultant only
Use as per GMMMMG Macular Drugs Pathway |
04.03.04 |
Agomelatine |
Agomelatine may have a role for specialist initiation, but only in those patients with severe depression who have already failed on all classes of antidepressant therapies. |
05.05.01 |
Albendazole |
Tablets
unlicensed |
05.05.03 |
Albendazole |
Tablets
unlicensed |
05.05.04 |
Albendazole |
See section 5.5.1. |
05.05.07 |
Albendazole |
Tablets
unlicensed |
05.05.08 |
Albendazole |
Tablets
unlicensed |
08.02.03 |
Alemtuzumab MabCampath® |
Concentrate for intravenous infusion
Specialist use only
Patient access scheme may be available. Patient access and monitoring form available from pharmacy. |
24.03 |
Alemtuzumab IV Infusion |
|
24.03 |
Alemtuzumab SC Injection |
|
06.06.02 |
Alendronic Acid |
70mg tablets (once weekly preparation)
|
09.06.04 |
Alfacalcidol One-Alpha® |
Capsules
Oral Solution
For maintenance, not for treatment.
Frequency of plasma calcium monitoring should be determined by secondary care clinicians and communicated to primary care |
15.01.04.03 |
Alfentanil Rapifen® |
|
07.04.01 |
Alfuzosin |
M/R tablets |
03.04.01 |
Alimemazine |
Tablets
Oral Solution
On formulary for paediatric use only
|
02.12 |
Alirocumab Praluent® |
Pre-filled syringe Pre-filled pen
For patients with latex allergy or intolerance to evolocumab
Only as per NICE TA393. Requires completion of Blueteq form prior to initiation. Available via Homecare providers.
|
13.05.01 |
Alitretinoin Toctino® |
Capsules
Dermatology (Salford Royal) only |
10.01.04 |
Allopurinol |
Tablets |
06.01.02.03 |
Alogliptin Vipidia® |
Tablets
|
09.06.05 |
Alpha Tocopheryl Acetate |
Oral suspension |
13.09 |
Alphosyl 2 in 1® Coal Tar Extract 5% (Alcoholic) |
Shampoo |
07.04.05 |
Alprostadil |
Caverject® intracavernosal injection
MUSE® urethral application |
02.10.02 |
Alteplase Actilyse® |
Actilyse Injection
Actilyse Cathflo 2mg (for thrombolytic treatment of occluded central venous access devices)is restricted to NMGH Renal Unit only;
Approved for pulmonary embolism, acute ischaemic stroke (FGH only) and thrombolysis in acute limb ischaemia.
Alteplase is recommended for the treatment of acute ischaemic stroke in adults in accordance with its licensed indication if:
treatment is started as early as possible within 4.5 hoursof onset of stroke symptoms, AND
intracranial haemorrhage has been excluded by appropriate imaging techniques
See NICE TA264
|
13.12 |
Aluminimum Chloride Hexahydrate 20% in Alcoholic Base Anhydrol Forte® or Driclor® |
|
09.05.02.02 |
Aluminium Hydroxide Alu-Cap® |
475mg capsules
|
01.02 |
Alverine Citrate Spasmonal® |
|
04.09.01 |
Amantadine Hydrochloride |
Capsules
Syrup |
24.01 |
Ambisome IV Infusion |
|
24.01 |
Ambisome IV Syringe 1mg/ml |
|
05.01.04 |
Amikacin |
Injection
Can only be prescribed for intravenous use following discussion with the Consultant Microbiologist or ID Physician
|
02.02.03 |
Amiloride |
Tablets
Liquid
|
13.08.01 |
Aminolevulinic acid Metvix |
Cream
Dermatology Only |
03.01.03 |
Aminophylline |
Modified release tablets
Injection
|
02.03.02 |
Amiodarone |
Tablets
Infusion
Injection (emergency use only)
Specialist initiation only
|
04.02.01 |
Amisulpride |
Tablets
Oral solution
RED when prescribed for new patients with dementia or other unlicensed indications |
04.03.01 |
Amitriptyline |
Tablets
Oral solution |
04.07.03 |
Amitriptyline |
Tablets Oral solution |
06.01.05 |
Amitriptyline |
Tablets Oral solution
unlicensed |
02.06.02 |
Amlodipine |
Tablets |
13.10.02 |
Amorolfine Loceryl® |
Dermatology Only |
05.01.01.03 |
Amoxicillin |
Capsules
Oral Suspension
Sachets
Injection |
05.02.03 |
Amphotericin AmBisome® |
Intravenous Infusion
Prepared by pharmacy aseptics during working hours. Liaise with pharmacy. |
11.03.02 |
Amphotericin |
0.15% eye drops
First line for yeast-type fungi
Ophthalmic consultant initiation only
|
24.03 |
Amsacrine IV Infusion |
|
09.01.04 |
Anagrelide Xagrid® |
Capsules |
08.03.04.01 |
Anastrozole Arimidex® |
Tablets
|
11.04.02 |
Antazoline 0.5% with Xylometazoline 0.05% Otrivine-Antistin® |
Eye drops |
13.08.01 |
Anthelios® Melt In Cream SPF50 |
Cream
Dermatology Only |
14.05.03 |
Anti-D (Rh0) Immunoglobulin |
|
09.01.03 |
Anti-human thymocyte immunoglobulin (rabbit) Thymoglobuline® |
|
01.07.01 |
Anusol® |
Cream
Suppositories |
01.07.02 |
Anusol-HC® |
Ointment
Suppositories |
06.01.01.01 |
Apidra® Insulin Glulisine |
3ml cartridge (via ClikSTAR® or Autopen® 24)
3ml pre-filled disposable pen (SoloStar®)
|
02.08.02 |
Apixaban Eliquis |
Tablets |
02.08.02 |
Apixaban Eliquis |
Tablets |
04.09.01 |
Apomorphine Injection |
Initiation on the recommendation of a movement disorder specialist only |
11.06 |
Apraclonidine Iopidine® |
Eye drops
Ophthalmic consultant initiation only: Apraclonidine can be used long term for certain complex glaucoma cases where surgery is high risk. See also section 11.8.
1% - unlicensed use |
11.08.02 |
Apraclonidine Iopidine® |
0.5% Eye drops
1% Single-use eye drops
Apraclonidine 1% is licensed for control or prevention of postoperative elevation of intraocular pressure after anterior segment laser surgery.
See also section 11.06.
Ophthalmic specialist initiation only
|
10.01.03 |
Apremilast Otezla® |
Tablets |
13.02.01.01 |
Aqueous Cream BP |
|
06.02.02 |
Aqueous Iodine Oral Solution Lugol's |
Oral solution |
01.06.03 |
Arachis Oil Enema |
|
04.02.01 |
Aripiprazole |
Tablets
Orodispersible tablets
Oral solution
Injection (IM)
RED when prescribed for new patients with dementia or other unlicensed indications |
04.02.02 |
Aripiprazole Abilify Maintena® |
Vial
|
24.03 |
Arsenic Trioxide IV Infusion |
|
05.04.01 |
Artemether with lumefantrine Riamet® |
Tablets |
05.04.01 |
Artesunate |
Injection
unlicensed
|
09.06.03 |
Ascorbic Acid |
Tablets
|
04.02.03 |
Asenapine |
Sublingual tablets
Pennine Care: may be considered third line for inpatients who have failed to respond or failed to tolerate existing therapies. |
02.09 |
Aspirin (antiplatelet) |
Dispersible tablets
Gastro-resistant (enteric coated) tablets (only for patients established on this product)
Tablets
See information above.
Low dose aspirin prophylaxis should not routinely be initiated for primary prevention.
Enteric-coated aspirin tablets are not recommended. There is no convincing evidence that at a daily dose of 75mg using enteric coated rather than soluble aspirin reduces the risk of gastrointestinal bleeding. (Ref: Drug Ter Bull. Jan 1997, p7-8). |
05.03.01 |
Atazanavir Reyataz® |
|
05.03.01 |
Atazanavir and Cobicistat Evotaz® |
Tablets |
02.04 |
Atenolol |
Tablets
Syrup
Injection |
04.04 |
Atomoxetine |
Mental health services only |
02.12 |
Atorvastatin |
Tablets
30mg and 60mg tablets are not to be prescribed![]()
|
07.01.03 |
Atosiban Tractocile® |
Not to be initiated at Pennine Acute Trust |
05.04.08 |
Atovaquone |
Oral suspension |
15.01.05 |
Atracurium Besilate |
|
15.01.03 |
Atropine |
|
11.05 |
Atropine Sulphate |
0.5% eye drops
1% eye drops
1% single-use eye drops (Minims®)
|
13.02.01 |
Aveeno® |
Cream
Dermatology only |
24.03 |
Azacitadine SC Injection |
|
01.05.03 |
Azathioprine |
Tablets |
08.02.01 |
Azathioprine |
Tablets
Injection
Red if there is no shared care protocol (licensed indications only)
|
10.01.03 |
Azathioprine |
Tablets |
13.05.03 |
Azathioprine |
Tablets
unlicensed indication (severe refractory eczema) |
05.01.05 |
Azithromycin |
Capsules
Tablets
Oral Suspension |
11.03.01 |
Azithromycin Azyter® |
Eye drop solution in single-dose container
For use in paediatric conjunctivitis - see policy |
05.01.02.03 |
Aztreonam |
Injection
Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician |
09.06.02 |
B Vitamins, High Potency Pabrinex® |
Intravenous Injection
Intramuscular Injection |
10.02.02 |
Baclofen |
Tablets
Oral solution |
13.02.01.01 |
Balneum Plus Bath Oil |
|
13.02.01 |
Balneum® Plus cream |
Cream |
01.05.01 |
Balsalazide Sodium Colazide® |
Capsules
Specialist initiation only |
10.01.03 |
Baricitinib Olumiant® |
Tablets |
24.02 |
BBraun Nutriflex Lipid Peri 1250 |
Additions of electrolytes available on request |
24.02 |
BBraun Nutriflex Lipid Peri 1875 |
Additions of electrolytes available on request |
24.02 |
BBraun Nutriflex Lipid Peri 2500 |
Additions of electrolytes available on request |
24.02 |
BBraun Nutriflex Lipid Plus 2500 |
Additions of electrolytes available on request |
24.02 |
BBraun Nutriflex Lipid Special 1250 |
Additions of electrolytes available on request |
24.02 |
BBraun Nutriflex Lipid Special 1875 |
Additions of electrolytes available on request |
24.02 |
BBraun Nutriflex Lipid Special 1875 EF |
Additions of electrolytes available on request |
24.02 |
BBraun Nutriflex Special 1500 |
Additions of electrolytes available on request |
07.04.04 |
BCG (Bacillus Calmette-Guerin) |
Bladder instillation |
08.02.04 |
BCG bladder instillation OncoTICE® |
Specialist use only |
14.04 |
BCG vaccine diagnostic agent Tuberculin PPD |
|
14.04 |
BCG vaccine Intradermal |
|
03.02 |
Beclometasone Qvar® |
Metered Dose Inhaler (MDI)
Easi-breathe®
Autohaler®
Not licensed for use in paediatrics. |
03.02 |
Beclometasone Clenil Modulite® |
Metered Dose Inhaler (MDI) |
03.02 |
Beclometasone / formoterol / glycopyrronium Trimbow® |
Metered dose inhaler (MDI)
Combination ICS/LABA/LAMA inhaler |
03.02 |
Beclometasone and formoterol Fostair® |
- Metered dose inhaler (MDI)
- Dry powder inhaler (NEXThaler®)
Combination ICS/LABA inhaler
Fostair® contains an extra-fine formulation of beclomethasone and is more potent than traditional CFC-containing beclomethasone inhalers - check dose.
200/6 strength only licensed in asthma
|
12.02.01 |
Beclometasone Dipropionate |
Nasal Spray |
05.01.09 |
Bedaquiline Sirturo® |
Tablets
Can only be prescribed after discussion with an ID physician |
03.04.02 |
Bee and Wasp Allergen Extracts Pharmalgen® |
Subcutaneous injection
Specialist Use Only |
24.03 |
Bendamustine IV Infusion |
|
02.02.01 |
Bendroflumethiazide |
Tablets
Not first line for hypertension (see NICE CG127: Hypertension). Patients with stable and controlled blood pressure currently taking bendroflumethiazide can continue treatment.
|
03.04.02 |
Benralizumab Fasenra® |
Subcutaneous injection |
10.01.04 |
Benzbromarone |
Tablets
unlicensed
|
12.03.01 |
Benzocaine |
Anaesthetic gel |
13.06.01 |
Benzoyl Peroxide 2.5 - 10% |
Gel
Lotion
|
13.06.01 |
Benzoyl Peroxide with antimicrobials Quinoderm® |
Cream |
12.03.01 |
Benzydamine Difflam® |
Mouthwash Oromucosal Spray
To only be prescribed in paediatrics with consultant approval
|
05.01.01.01 |
Benzylpenicillin |
Injection
|
04.06 |
Betahistine |
Tablets |
04.06 |
Betahistine Dihydrochloride |
|
06.03.02 |
Betamethasone |
Injection
Soluble tablets |
11.04.01 |
Betamethasone |
Eye/ear/nose drops
Eye ointment |
13.04 |
Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic® |
Ointment
Scalp Application |
13.04 |
Betamethasone (as Valerate) 0.025% Betnovate-RD® |
Cream
Ointment |
13.04 |
Betamethasone (as Valerate) 0.1% Non-proprietary or Betnovate® |
Cream
Ointment |
13.04 |
Betamethasone (as Valerate) 0.1% Betnovate Scalp® |
Scalp application |
13.04 |
Betamethasone (as Valerate) 0.1% with Clioquinol Non proprietary or Betnovate-C® |
Cream
Ointment |
13.04 |
Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% Fucibet® |
Cream |
13.04 |
Betamethasone (as Valerate) 0.1% with Neomycin Sulphate 0.5% Non-proprietary or Betnovate-N® |
Cream
Ointment |
12.01.01 |
Betamethasone 0.1% with Neomycin 0.5% drops Betnesol N® |
Ear/eye/nose drops |
12.01.01 |
Betamethasone 0.1% with Neomycin 0.5% drops Betnesol N® |
Ear/eye/nose drops |
13.04 |
Betamethasone Dipropionate 0.064% with Clotrimazole 1% Lotriderm® |
Cream |
12.01.01 |
Betamethasone drops |
Ear/eye/nose drops
|
12.02.01 |
Betamethasone drops |
Eye/ear/nose drops |
13.04 |
Betamethasone Valerate 0.1% Scalp Application Betacap® |
Scalp application |
11.04.01 |
Betamethasone with Neomycin |
Eye/ear/nose drops |
11.06 |
Betaxolol |
Eye drops
Unit dose eye drops |
11.08.02 |
Bevacizumab intravitreal injection |
Ocular injection
Named-patient use only. For existing patients only. Ophthalmic consultant only
unlicensed |
08.03.04.02 |
Bicalutamide |
Tablets
|
11.06 |
Bimatoprost Lumigan® |
Eye drops
Single-use eye drops
|
11.06 |
Bimatoprost with Timolol Ganfort® |
Eye drops
Single-use eye drops
Combination products are licensed for once daily use where prostaglandin analogue alone is not adequate. Only use where patient has difficulty with compliance/administration.
|
12.03.05 |
Biotene Oralbalance® |
Saliva replacement gel |
09.08.01 |
Biotin |
Tablets
unlicensed
|
12.03.05 |
BioXtra® |
Gel |
01.06.02 |
Bisacodyl |
Tablets
Suppositories |
02.04 |
Bisoprolol |
Tablets |
24.03 |
Bleomycin IV Infusion |
|
24.03 |
Bortezomib SC Injection |
|
04.09.03 |
Botulinum Toxin Type A Botox® |
|
04.09.03 |
Botulinum Toxin Type A Dysport® |
|
24.03 |
Brentuximab IV Infusion |
|
11.06 |
Brimonidine Tartrate Alphagan® |
Eye drops
|
11.06 |
Brimonidine Tartrate 0.2% with Timolol 0.5% Combigan® |
Eye drops
Combination products are licensed for use when beta blocker monotherapy does not provide adequate treatment. Only use where patient has difficulty with compliance/administration.
|
11.06 |
Brinzolamide Azopt® |
Eye drops
|
11.06 |
Brinzolamide 1% with Timolol 0.5% Azarga® |
Eye drops
Only use combination products where patient has difficulty with compliance/administration. |
11.08.02 |
Bromfenac Yellox® |
0.9mg/mL eye drops
(Not on GMMMG formulary) |
06.07.01 |
Bromocriptine |
Tablets
Capsules
|
01.05.02 |
Budesonide Entocort® |
C/R capsules
Specialist initiation only: for treatment resistant terminal-ileal Crohn's disease |
03.02 |
Budesonide |
Dry powder inhaler (Easyhaler®, Pulmicort® Turbohaler)
Respules |
03.02 |
Budesonide and formoterol Fobumix® |
Metered dose inhaler (Easyhaler®)
Combination ICS/LABA inhaler
80/4.5 strength only licensed in asthma
|
03.02 |
Budesonide and formoterol DuoResp® Spiromax |
Dry powder inhaler
Combination ICS/LABA inhaler
|
02.02.02 |
Bumetanide |
Tablets
Liquid
Injection has been discontinued
|
15.02 |
Bupivacaine and Adrenaline |
|
15.02 |
Bupivacaine Hydrochloride |
|
15.02 |
Bupivacaine with Fentanyl |
|
04.07.02 |
Buprenorphine |
Patches (BuTrans® or Transtec®)
S/L tablets (Temgesic®) |
04.10.03 |
Buprenorphine Subutex® |
Sublingual tablets |
04.10.02 |
Bupropion Hydrochloride Zyban® |
|
04.09.01 |
Cabergoline |
Tablets |
06.07.01 |
Cabergoline |
Tablets |
09.05.01.01 |
Cacit® |
Effervescent tablets |
13.03 |
Calamine |
Cream
Lotion |
13.05.02 |
Calamine and Coal Tar Ointment |
Ointment |
09.05.01.01 |
Calcichew® |
Chewable tablets |
13.05.02 |
Calcipotriol |
Ointment
Scalp solution
To be commenced on advice of dermatology only |
13.05.02 |
Calcipotriol 50micrograms/g with Betamethasone 0.05% Dovobet® |
Ointment
Gel
To be commenced on advice of dermatology only |
06.06.01 |
Calcitonin (salmon) / Salcatonin |
Injection |
09.06.04 |
Calcitriol |
Capsules
For maintenance, not for treatment |
13.05.02 |
Calcitriol 3micrograms/g Silkis® |
Ointment
To be commenced on advice of dermatology only |
09.05.02.02 |
Calcium Acetate Phosex® |
1 gram tablets
|
09.06.04 |
Calcium and Colecalciferol Calceos® |
Chewable tablets |
09.06.04 |
Calcium and colecalciferol Calfovit D3® |
Sachets |
09.05.02.02 |
Calcium Carbonate Calcichew® |
500mg chewable tablets
|
09.05.01.01 |
Calcium Chloride 10% Injection |
Injection |
05.04.07 |
Calcium Folinate |
|
05.04.07 |
Calcium Folinate |
Tablets
Injection |
08.01 |
Calcium Folinate |
Tablets
Injection |
09.05.01.01 |
Calcium Gluconate 10% Injection |
Injection
|
13.02.01 |
Calmurid® |
Cream |
09.04 |
Calogen |
Dose calculated by dietitian |
06.01.02.03 |
Canagliflozin Invokana® |
Tablets |
02.05.05.02 |
Candesartan |
Tablets |
13.09 |
Capasal® Shampoo |
Shampoo |
05.01.09 |
Capreomycin Capastat® |
Intramuscular Injection
Can only be prescribed following discussion with an ID physician |
06.01.05 |
Capsaicin |
Cream 0.075& |
10.03.02 |
Capsaicin |
0.025% cream (adjunct in hand or knee osteoarthritis)
0.075% cream (postherpetic neuralgia and diabetic neuropathy)
|
02.05.05.01 |
Captopril |
Tablets
Oral solution unlicensed. For paediatric use only
Not as per GMMMG for adults |
04.02.03 |
Carbamazepine |
Tablets
M/R tablets
Liquid
Suppositories
|
04.07.03 |
Carbamazepine |
Tablets
M/R tablets
Liquid
Suppositories
|
04.08.01 |
Carbamazepine |
Tablets
M/R tablets
Liquid
Suppositories
Ensure patients are maintained on a specific manufacturer's product / brand |
06.02.02 |
Carbimazole |
Tablets
|
03.07 |
Carbocisteine |
Capsules
Liquid
|
11.08.01 |
Carbomers |
Eye drops
Single-use eye drops
Brand with lowest aquisition cost will be supplied. |
24.03 |
Carboplatin IV Infusion |
|
07.01.01 |
Carboprost Hemabate® |
Injection |
24.03 |
Carfilzomib IV Infusion |
|
11.08.01 |
Carmellose |
Eye drops
Single-use eye drops
Brand with lowest aquisition cost will be supplied. |
12.03.01 |
Carmellose Sodium Orabase® |
Oral paste |
12.03.01 |
Carmellose Sodium Orahesive® |
Powder |
09.08.01 |
Carnitine Carnitor® |
|
11.06 |
Carteolol Teoptic® |
Eye drops |
02.04 |
Carvedilol |
Tablets |
05.02.04 |
Caspofungin Cancidas® |
Intravenous Infusion
Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician |
07.04.04 |
Catheter Patency Solutions Solution R Uro-Tainer® |
|
07.04.04 |
Catheter Patency Solutions Sodium Chloride 0.9% Uro-Tainer® |
|
13.02.02 |
Cavilon®Film |
Barrier Preparation
Obtained through SUPPLIES not pharmacy |
13.09 |
Ceanel Concentrate® Shampoo |
Shampoo |
05.01.02.01 |
Cefalexin |
Capsules
Tablets
Oral Suspension |
05.01.02.01 |
Cefixime |
Tablets
Oral Suspension |
05.01.02.01 |
Cefotaxime |
Injection |
24.01 |
Cefoxitin IV Infusion |
3gram Infusor |
05.01.02.01 |
Ceftazidime |
Injection |
24.01 |
Ceftazidime IV infusion |
3gram ECLIPSE pump |
05.01.02.01 |
Ceftazidime with avibactam Zavicefta® |
Powder for solution for infusion |
05.01.02.01 |
Ceftriaxone |
Injection |
24.01 |
Ceftriaxone IV infusion |
50mg/mL |
05.01.02.01 |
Cefuroxime Zinacef® |
Injection
Tablets
Oral Suspension |
11.03.01 |
Cefuroxime |
Eye drops unlicensed special
STORE IN FREEZER PRIOR TO USE. Once thawed, store in fridge for a maximum of 7 days.
|
10.01.01 |
Celecoxib Celebrex® |
Capsules |
10.01.03 |
Certolizumab Pegol |
Subcutaneous Injection
|
12.01.03 |
Cerumol® |
Ear drops
Not on GMMMG Formulary |
03.04.01 |
Cetirizine |
Tablets
Oral solution |
13.02.01 |
Cetraben® |
Cream
|
13.10.05 |
Cetrimide 0.5% Cream |
Cream |
04.01.01 |
Chloral Hydrate 500mg in 5mL |
|
05.01.07 |
Chloramphenicol |
Injection
(Oral preparations are non-formulary) |
11.03.01 |
Chloramphenicol |
Eye drops
Eye ointment
Single use eye drops (Minims®)
|
04.10.01 |
Chlordiazepoxide |
Capsules |
11.03.01 |
Chlorhexidine |
Eye drops unlicensed special
Used with propamidine for acanthamoeaba keratitis only |
12.03.04 |
Chlorhexidine Gluconate |
Mouthwash
Dental gel
Oral spray |
12.02.03 |
Chlorhexidine Hydrochloride 0.1%, Neomycin Suphate 0.5% Naseptin® |
Cream
Contains PEANUT oil |
05.04.01 |
Chloroquine |
Tablets
Syrup |
02.02.01 |
Chlorothiazide |
Suspension
unlicensed
Paediatric use only |
03.04.01 |
Chlorphenamine |
Tablets
Oral Solution |
04.02.01 |
Chlorpromazine |
Tablets
Oral solution
Injection |
14.04 |
Cholera vaccine Dukoral® |
NMGH Travel Clinic only |
12.03.01 |
Choline Salicylate Bonjela® Adult |
Oral gel
For over 16 years of age only |
06.05.01 |
Chorionic Gonadotrophin Pregnyl® |
Injection |
01.05.03 |
Ciclosporin |
Capsules (Neoral®)
Concentrate for intravenous infusion (Sandimmun®)
MUST be prescribed by brand |
08.02.02 |
Ciclosporin |
Capsules
Oral solution
Prescribe by brand. Do not switch between brands.
Brands:
Capimune®
Capsorin®
Deximune®
Neoral®
Red if no shared care protocol (licensed indications only)
|
10.01.03 |
Ciclosporin |
Capsules
Prescribe by brand
|
11.08.01 |
Ciclosporin Ikervis® |
1mg/mL eye drop emulsion
Treatment of severe keratitis in adult patients with dry eye disease not responsive to tear substitutes.
|
13.05.03 |
Ciclosporin |
Capsules
Oral Solution
Must be prescribed by BRAND. (See Section 8.2.2.)
|
05.03.02.02 |
Cidofovir Vistide® |
|
24.03 |
Cidofovir IV Infusion |
|
07.03.01 |
Cilest® Ethinylestradiol 35 mcg / norgestimate 250 mcg |
Standard strength preparation |
09.05.01.02 |
Cinacalcet Mimpara® |
Tablets
Use is subject to a local shared-care agreement with the patient's GP (see link) |
04.06 |
Cinnarizine |
Tablets |
04.06 |
Cinnarizine |
|
05.01.12 |
Ciprofloxacin |
Tablets
Oral Suspension
Intravenous Infusion: requires microbiology/ID consultant approval, unless use is in line with antibiotic policy |
11.03.01 |
Ciprofloxacin |
Eye drops
|
15.01.05 |
Cisatracurium Nimbex® |
|
24.03 |
Cisplatin IV Infusion |
|
04.03.03 |
Citalopram |
Tablets
Oral drops |
24.03 |
Cladribine IV Infusion |
|
24.03 |
Cladribine SC Injection |
|
05.01.05 |
Clarithromycin |
Tablets
Oral Suspension
Intravenous Infusion
|
24.01 |
Clarithromycin IV Infusion |
500mg in 250mL sodium chloride 0.9% |
05.01.06 |
Clindamycin |
Capsules
Injection |
05.04.07 |
Clindamycin |
Capsules
Injection |
05.04.08 |
Clindamycin |
Capsules
Injection |
07.02.02 |
Clindamycin |
Cream |
13.06.01 |
Clindamycin 1% Dalacin T® |
Topical solution |
13.06.01 |
Clindamycin 1% Zindaclin® |
Gel |
04.08.01 |
Clobazam |
Tablets
Oral suspension |
13.04 |
Clobetasol Propionate 0.05% Dermovate® |
Cream
Ointment
Scalp Application |
13.04 |
Clobetasol Propionate 0.05% Etrivex® |
Shampoo
Dermatology only |
13.04 |
Clobetasone Butyrate 0.05% Eumovate® |
Cream
Ointment |
13.04 |
Clobetasone butyrate 0.05% with Oxytetracycline and Nystatin Trimovate® |
Cream |
24.03 |
Clofarabine SC Injection |
|
05.01.10 |
Clofazimine |
Capsules
Can only be prescribed following discussion with an ID physician |
06.05.01 |
Clomifene Citrate |
Tablets
Only indicated for patients in whom ovulatory dysfunction has been demonstrated and other causes of infertility have been excluded or adequately treated |
04.03.01 |
Clomipramine |
Capsules
M/R tablets
Included as first choice in the treatment of OCD only |
04.08.01 |
Clonazepam |
Tablets
Injection |
02.05.02 |
Clonidine Hydrochloride |
Tablets |
02.09 |
Clopidogrel |
Tablets
See information above. |
07.02.02 |
Clotrimazole |
Cream
Pessary |
12.01.01 |
Clotrimazole Canesten® |
1% solution |
13.10.02 |
Clotrimazole 1% |
Cream
Solution
Spray |
04.02.01 |
Clozapine Clozaril® |
Clozapine is only indicated for treatment resistant schizophrenia.
Prescribers, pharmacies and patients must be registered with the relevant supplier’s patient monitoring service. |
04.02.01 |
Clozapine Zaponex® |
Clozapine is only indicated for treatment resistant schizophrenia.
Prescribers, pharmacies and patients must be registered with the relevant supplier’s patient monitoring service. |
13.05.02 |
Coal Tar 1% Lotion |
Lotion |
13.05.02 |
Coal Tar and Salicylic Acid in Unguentum M |
To be commenced on advice of dermatology only
|
13.05.02 |
Coal Tar in Salicylic Acid Ointment |
Ointment |
13.05.02 |
Coal Tar in Yellow Soft Paraffin |
0.5%
1%
3%
5%
10%
15%
20%
25% |
13.05.02 |
Coal Tar Paste |
Paste |
02.02.04 |
Co-amilofruse (amiloride and furosemide) |
Tablets Although it is preferable to prescribe potassium-sparing diuretics and loop diuretics separately, the use of fixed combinations may be justified if compliance is a problem (BNF). |
02.02.04 |
Co-amilozide |
Tablets Although it is preferable to prescribe potassium-sparing diuretics and thiazide diuretics separately, the use of fixed combinations may be justified if compliance is a problem (BNF). |
05.01.01.03 |
Co-Amoxiclav |
Tablets
Oral Suspension
Injection
Co-amoxiclav is only recommended as first line treatment in specific indications. Refer to Antibiotic Policy.
The risk of acute liver toxicity is 6 times greater with co-amoxiclav than with amoxicillin. Cholestatic jaundice is more common in patients above the age of 65 and in males. The duration of treatment should not normally exceed 14 days.
Co-amoxiclav is a recognised cause of Clostridium difficile infections and its use should be restricted. |
04.09.01 |
Co-Beneldopa Madopar® |
Capsules
Dispersible tablets
M/R capsules |
05.03.01 |
Cobicistat Tybost® |
Tablets
Requires MDT discussion with ID team |
11.07 |
Cocaine |
Eye drops
unlicensed |
04.09.01 |
Co-Careldopa Sinemet® |
Tablets
M/R tablets |
04.09.01 |
Co-Careldopa and Entacapone Stalevo® |
Tablets |
13.06.02 |
Co-Cyprindiol 2000/35 (Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms) Dianette® |
Tablets |
13.09 |
Co-Cyprindiol 2000/35 (Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms) Dianette® |
Tablets |
01.06.02 |
Co-danthramer |
Capsules
Strong capsules
Suspension
Strong suspension
Specialist use: Palliative care only |
01.06.02 |
Co-danthrusate |
Capsules
Suspension
Specialist use: Palliative care only |
01.04.02 |
Codeine |
Tablets
Oral solution |
03.09.01 |
Codeine Linctus BP |
Oral solution
|
04.07.02 |
Codeine Phosphate |
Tablets
Oral liquid |
10.01.04 |
Colchicine |
Tablets |
09.06.04 |
Colecalciferol |
Capsules
Oral solution
|
09.06.04 |
Colecalciferol and Calcium Carbonate Calcichew-D3® |
Chewable tablets |
09.06.04 |
Colecalciferol and Calcium Carbonate Calcichew-D3® Forte |
Chewable tablets |
09.06.04 |
Colecalciferol and Calcium Carbonate Adcal-D3® |
Chewable Tablets
Caplets
Effervescent Tablets
|
01.09.02 |
Colestyramine Questran Light® |
|
02.12 |
Colestyramine |
Powder |
05.01.07 |
Colistimethate |
Intravenous injection
Injection for nebulisation (Colomycin® brand)
Powder for nebuliser solution
GMMMG RAG status when nebulised:
RED for cystic fibrosis patients
AMBER for non-cystic fibrosis patients
|
10.03.01 |
Collagenase Xiapex® |
Intralesional injection
Individual funding request is NOT required when used for Dupytren's contracture that is moderate in nature. Defined as:
Notable functional problems,
AND one of the following:
Moderate metacarpo-phalangeal joint contracture (30° – 60°)
OR
Moderate proximal inter-phalangeal joint contracture (<30°)
OR
First web contracture.
For all other indications (e.g. Frozen Shoulder / Peyronie's Disease / any other use / non-moderate Dupytren's) an individual funding request is required. |
01.01.01 |
Co-magaldrox suspension |
|
09.02.02.01 |
Compound Sodium Lactate Intravenous Infusion |
500ml bag
1 litre bag |
13.02.02 |
Conotrane® |
Cream |
05.01.08 |
Co-trimoxazole |
Tablets
Oral Suspension
Intravenous Infusion
|
05.04.08 |
Co-trimoxazole |
See section 5.1.8. |
13.03 |
Crotamiton Eurax® |
Cream
Lotion |
13.11.06 |
Crystacide® Hydrogen Peroxide 1% |
Cream |
13.11.02 |
CX Antiseptic Dusting Powder® Chlorhexidine |
|
09.01.02 |
Cyanocobalamin |
Tablets
Only for use in those patients who are truly unable to tolerate injections and who are vegan or have a proven dietary deficiency. |
04.06 |
Cyclizine |
Tablets Injection |
04.06 |
Cyclizine |
Tablets Injection |
04.06 |
Cyclizine |
Tablets Injection |
04.06 |
Cyclizine |
Tablets Injection |
04.06 |
Cyclizine |
Tablets
Injection |
11.05 |
Cyclopentolate Hydrochloride |
0.5% and 1% eye drops
0.5% and 1% single-use eye drops (Minims®)
|
10.01.03 |
Cyclophosphamide |
Tablets
Injection |
24.03 |
Cyclophosphamide IV Infusion |
|
24.03 |
Cyclophosphamide IV Injection |
|
24.03 |
Cyclophosphamide, Etoposide and Cisplatin IV Infusion |
|
05.01.09 |
Cycloserine |
Capsules
Can only be prescribed following discussion with an ID physician |
06.04.02 |
Cyproterone Acetate |
Tablets |
08.03.04.02 |
Cyproterone Acetate |
Tablets
Following specialist initiation
|
24.03 |
Cytarabine Intrathecal Injection |
|
24.03 |
Cytarabine IV Infusion |
|
24.03 |
Cytarabine IV Injection |
|
24.03 |
Cytarabine SC Injection |
|
02.08.02 |
Dabigatran Pradaxa® |
Capsules
Praxbind® (idarucizumab) is a specific reversal agent for dabigatran. This may be used on the advice of a haematologist only - see PAT guideline: Management of Bleeding in Patients Receiving Anti-thrombotic Agents. |
02.08.02 |
Dabigatran Pradaxa® |
Capsules
Praxbind® (idarucizumab) is a specific reversal agent for dabigatran. This may be used on the advice of a haematologist only - see PAT guideline: Management of Bleeding in Patients Receiving Anti-thrombotic Agents. |
02.08.02 |
Dabigatran Pradaxa® |
Capsules
Praxbind® (idarucizumab) is a specific reversal agent for dabigatran. This may be used on the advice of a haematologist only - see PAT guideline: Management of Bleeding in Patients Receiving Anti-thrombotic Agents. |
24.03 |
Dacarbazine IV Infusion |
|
05.03.03.02 |
Daclatasvir Daklinza® |
Tablets
Requires MDT discussion with ID team |
02.08.01 |
Danaparoid Orgaran® |
Injection
For prevention and treatment of thromboembolic disease in patients with a history of heparin-induced thrombocytopenia.
|
06.07.02 |
Danazol |
Capsules |
10.02.02 |
Dantrolene |
Capsules |
15.01.08 |
Dantrolene Sodium Dantrium Intravenous® |
|
06.01.02.03 |
Dapagliflozin Forxiga® |
Tablets
|
05.01.10 |
Dapsone |
Tablets |
05.04.08 |
Dapsone |
Tablets |
05.01.07 |
Daptomycin |
Intravenous Infusion
Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician |
24.03 |
Daratumumab IV Infusion |
|
09.01.03 |
Darbepoetin Alfa Aranesp® |
Injection |
05.03.01 |
Darunavir Prezista® |
|
05.03.01 |
Darunavir and Cobicistat Rezolsta® |
Tablets |
05.03.03.02 |
Dasabuvir Exviera® |
Tablets
Requires MDT discussion with ID team |
24.03 |
Daunorubicin IV Infusion |
|
24.03 |
Daunorubicin liposomal IV Infusion |
|
09.01.03 |
Deferasirox Exjade® |
Dispersible tablets
PbR Excluded - commissioned by NHS England |
09.01.03 |
Deferiprone Ferriprox® |
Tablets
PbR Excluded - commissioned by NHS England |
08.03.04.02 |
Degarelix Firmagon® |
Subcutaneous injection
Consultant prescribing only. For patients with prostate cancer with spinal metastases.
|
05.01.09 |
Delamanid Deltyba® |
Tablets
Can only be prescribed following discussion with an ID physician
|
06.05.02 |
Demeclocycline |
Capsules
See BNF for details of dosage in SIADH unlicensed |
06.06.02 |
Denosumab XGEVA® |
Injection |
06.06.02 |
Denosumab Prolia® |
Injection
|
13.02.01 |
Dermol® |
Cream
Dermol 500 Lotion |
13.02.01.01 |
Dermol® |
|
13.02.01.01 |
Dermol® 600 bath emollient |
|
09.01.03 |
Desferrioxamine Mesilate |
Injection
PbR Excluded- commissioned by NHS England |
15.01.02 |
Desflurane Suprane® |
|
06.05.02 |
Desmopressin |
Tablets
Sublingual tablets
Nasal Spray
Injection |
04.06 |
Dexamethasone |
Tablets Oral solution Injection |
06.03.02 |
Dexamethasone |
Tablets
Injection
Oral solution |
10.01.02.02 |
Dexamethasone |
Injection |
11.04.01 |
Dexamethasone |
Eye drops
Single use eye drops (Minims®)
|
11.04.01 |
Dexamethasone intravitreal implant Ozurdex® |
Intravitreal injection
Specialist use only |
12.01.01 |
Dexamethasone with Antibacterial Otomize® |
Ear Spray |
12.01.01 |
Dexamethasone with Antibacterial Sofradex® |
Eye/ear drops
Not on GMMMG formulary |
11.04.01 |
Dexamethasone with Antibacterials Sofradex® |
Eye/ear drops |
11.04.01 |
Dexamethasone with Neomycin and Polymyxin B sulphate Maxitrol® |
Eye drops
Eye ointment
|
04.04 |
Dexamfetamine |
|
08.01 |
Dexrazoxane Savene® |
Intravenous Infusion |
04.07.02 |
Diamorphine |
Injection |
04.01.02 |
Diazepam |
Tablets
Oral solution
Injection
Rectal tubes |
04.08.02 |
Diazepam |
Injection (emulsion)
Rectal tubes (rectal solution)
Use diazepam injection as first-line alternative only if lorazepam injection not available
|
10.02.02 |
Diazepam |
Tablets
Oral solution |
15.01.04.01 |
Diazepam |
|
10.01.01 |
Diclofenac |
Suppositories
Injection
Diclofenac is contraindicated in patients with established:
•ischaemic heart disease
•peripheral arterial disease
•cerebrovascular disease
•congestive heart failure (New York Heart Association [NYHA] classification II–IV)
Diclofenac treatment should only be initiated after careful consideration for patients with significant risk factors for cardiovascular events (eg, hypertension, hyperlipidaemia, diabetes mellitus, smoking).
|
11.08.02 |
Diclofenac Voltarol® Ophtha |
Eye drops
Single use eye drops
(Not on GMMMG formulary) |
05.03.01 |
Didanosine Videx® |
Tablets
Capsules
Only for patients already established on this treatment. |
05.05.06 |
Diethylcarbamazine |
Tablets
unlicensed
|
08.03.01 |
Diethylstilbestrol |
Tablets
|
02.01.01 |
Digoxin |
Tablets
Liquid
Injection
When switching from oral to intravenous digoxin, the intravenous dose should be approximately 70% of the oral dose.
GMMMG does not recommend digoxin as first-line for rate control of atrial fibrillation in ambulant patients.
For plasma concentration monitoring, blood should be taken at least 6 hours after a dose.
|
02.01.01 |
Digoxin specific antibody fragments Digifab® |
See link for SPC |
04.07.02 |
Dihydrocodeine |
Tablets
M/R tablets |
05.04.02 |
Diloxanide Furoate |
Tablets |
02.06.02 |
Diltiazem |
Standard tablets (60mg)
Modified release tablets
Modified release capsules
Specify the brand when prescribing a diltiazem preparation (except for 60mg tablet).
|
01.07.04 |
Diltiazem Cream 2% |
|
13.05.02 |
Dimethyl fumarate Skilarence® |
Tablets
Dermatology only |
07.04.04 |
Dimethyl Sulfoxide 50% Rimso-50® |
Bladder instillation |
13.10.04 |
Dimeticone Hedrin® |
Lotion |
07.01.01 |
Dinoprostone |
Pessaries (Propess®)
Vaginal Tablets (Prostin E2®) |
14.04 |
Diphtheria antitoxin |
Microbiology / ID recommendation only |
14.04 |
Diphtheria with Hib, pertussis, poliomyelitis and tetanus Pediacel® |
|
14.04 |
Diphtheria with Hib, pertussis, poliomyelitis and tetanus Infanrix-IPV + Hib® |
|
14.04 |
Diphtheria with pertussis, poliomyelitis and tetanus Repevax® |
|
14.04 |
Diphtheria with poliomyelitis and tetanus Revaxis® |
|
13.02.01 |
Diprobase® |
Cream
Ointment |
02.09 |
Dipyridamole |
Tablets
Modified Release Capsules
Oral suspension
See information above. |
02.09 |
Dipyridamole and Aspirin Asasantin® Retard |
Modified release capsules.
See information above. |
11.99.99.99 |
Disodium Edetate 0.37% |
Eye lotion |
06.06.02 |
Disodium Pamidronate |
Concentrate for Intravenous Infusion
Refer to Electrolyte Disturbances Guidelines for dosage in hypercalcaemia |
02.03.02 |
Disopyramide |
Capsules
(Injection discontinued)
|
04.10.01 |
Disulfiram Antabuse® |
Specialist initiation only |
13.05.02 |
Dithranol Dithrocream® |
Cream: 0.1%, 0.25%, 0.5%, 1%, 2%.
|
13.05.02 |
Dithranol in Zinc and Salicylic Acid in Lassar's Paste |
Paste
unlicensed |
02.07.01 |
Dobutamine |
Concentrate for intravenous infusion (dilute before use).
|
01.06.02 |
Docusate Sodium |
Capsules
Oral suspension |
05.03.01 |
Dolutegravir Tivicay ® |
Tablets |
05.03.01 |
Dolutegravir and Abacavir and Lamivudine Triumeq ® |
|
01.02 |
Domperidone |
Tablets
Suspension
unlicensed indication
Studies have shown that domperidone may be associated with a small increased risk of serious cardiac side effects.
These risks may be higher in patients older than 60 years and in patients who receive daily oral doses of more than 30 mg.
Domperidone should be used at the lowest effective dose for the shortest possible time
Maximum treatment duration should not exceed one week
Domperidone is contra-indicated in patients who are taking concomitant medication known to cause QT prolongation (such as ketoconazole and erythromycin) |
04.06 |
Domperidone |
Tablets
Suspension
Suppositories (unlicensed) |
04.11 |
Donepezil |
Tablets
Orodispersible tablets
Commissioning arrangements may vary and in some localities this is Green2 - check with relevant CCG |
02.07.01 |
Dopamine |
Concentrate for intravenous infusion (dilute before use). |
02.07.01 |
Dopexamine |
Concentrate for intravenous infusion (dilute before use). |
03.07 |
Dornase Alfa Pulmozyme® |
nebuliser solution
Must only be initiated within hospital for the treatment of cystic fibrosis.
|
11.06 |
Dorzolomide |
Eye drops
Unit dose eye drops
|
11.06 |
Dorzolomide 2% with Timolol 0.5% |
Eye drops
Unit dose eye drops
Only use combination products when patient has difficulty with compliance/administration.
|
13.02.01 |
DoubleBase® |
Gel |
03.05.01 |
Doxapram |
Intravenous injection
May also be given by intravenous infusion (unlicensed)
|
02.05.04 |
Doxazosin |
Tablets
Doxazosin is a fourth-line hypertension management option.
Modified release preparations of doxazosin are not approved by GMMMG. Consider converting any existing patients to standard release doxazosin, using the UKMi Medicines Q&A for guidance. |
07.04.01 |
Doxazosin |
Tablets |
07.04.04 |
Doxorubicin |
Bladder instillation
Liaise with Pharmacy Aseptics for preparation of this product |
24.03 |
Doxorubicin IV Infusion |
|
24.03 |
Doxorubicin IV Injection |
|
05.01.03 |
Doxycycline |
Capsules
Dispersible Tablets |
05.04.01 |
Doxycycline |
See section 5.1.3. |
13.06.02 |
Doxycycline |
Capsules
Alternative choice for acne and rosacea |
13.02.02 |
Drapolene® |
Cream |
02.03.02 |
Dronedarone Multaq® |
Tablets
Cardiologist/stroke physician initiation only
Dronedarone should only be initiated as a second line treatment option for non-permanent atrial fibrillation after:
standard NICE first line options are either cautioned/contraindicated or have failed
and if
amiodarone use is cautioned/intolerated
It should only be used in clinically stable patients, and is not recommended for those with NYHA Class III/IV heart failure.
Dronedarone is not recommended for patients with permanent AF.
See attached guidance for more information. |
03.01.05 |
Drug Delivery Device Volumatic® |
|
03.01.05 |
Drug Delivery Device AeroChamber Plus® |
|
06.01.02.03 |
Dulaglutide Trulicity® |
Disposable pen
Once-weekly preparation |
04.03.04 |
Duloxetine Cymbalta® |
|
04.07.03 |
Duloxetine Cymbalta® |
Capsules
Duloxetine may be considered as an option where other treatments have failed, or for a clear diagnosis of diabetic neuropathy. |
06.01.05 |
Duloxetine Cymbalta® |
Capsules
|
07.04.02 |
Duloxetine Yentreve® |
Capsules
For stress incontinence only |
13.08.01 |
Dundee reflective sun creams Dundee Block® |
Dermatology Only
unlicensed
|
06.04.02 |
Dutasteride Avodart® |
Tablets |
13.08.01 |
E45 Sun Reflective Sunscreen® |
Preparations with an SPF less than 30 should not be prescribed.
|
13.02.01 |
E45® Cream |
Cream
|
07.02.02 |
Econazole |
Cream |
02.08.02 |
Edoxaban Lixiana® |
Tablets |
02.08.02 |
Edoxaban Lixiana® |
Tablets |
05.03.01 |
Efavirenz Sustiva® |
|
13.09 |
Eflornithine 11.5% Cream Vaniqa® |
Dermatology only |
05.03.03.02 |
Elbasvir/Grazoprevir Zepatier® 50mg/100mg |
Tablets
Requires MDT discussion with ID team |
06.04.01.01 |
Elleste Duet® |
Tablets
Estradiol 1mg + norethisterone 1mg
Estradiol 2mg + norethisterone 1mg
|
06.04.01.01 |
Elleste-Solo® |
Tablets
Estradiol 1mg
Estradiol 2mg
|
09.01.04 |
Eltrombopag Revolade® |
Tablets
PbR Excluded - commissioned by CCG |
06.01.02.03 |
Empagliflozin Jardiance® |
Tablets |
05.03.01 |
Emtricitabine Emtriva® |
|
05.03.01 |
Emtricitabine 200mg, Rilpivirine 25mg and Tenofovir 245mg Eviplera® |
|
13.02.01.01 |
Emulsiderm® Liquid Emulsion |
|
13.02.01 |
Emulsifying Ointment BP |
Ointment |
02.05.05.01 |
Enalapril |
Tablets
|
09.04 |
Enfamil AR |
Dose dependent on age |
09.04 |
Enfamil olac |
Dose dependent on age |
05.03.01 |
Enfuvirtide Fuzeon® |
|
02.08.01 |
Enoxaparin |
Subcutaneous injection
Green2 or Green3 depending on indication. See GMMMG RAG list for full details |
02.01.02 |
Enoximone Perfan® |
Intravenous Injection |
09.04 |
Enshake |
Vanilla Chocolate Strawberry Banana
|
09.04 |
Ensure Compact 125ML |
Vanilla Strawberry Banana |
09.04 |
Ensure Plus Bottles 220ML |
Chocolate Strawberry Coffee Vanilla Raspberry Banana Orange Fruits of Forest Neutral Peach
|
09.04 |
Ensure Plus Creme |
Vanilla Neutral Chocolate Banana |
09.04 |
Ensure Plus Fibre 200ML |
Vanilla Chocolate Raspberry Banana Strawberry
|
09.04 |
Ensure Plus Juce 220ML |
Strawberry Fruit Punch Lemon & Lime Orange Peach Apple |
09.04 |
Ensure Plus Yoghurt Style 220ML |
Strawberry Swirl Orchard Peach
|
09.04 |
Ensure Twocal 200ML |
Banana vanilla Neutral Strawberry
|
04.09.01 |
Entacapone |
|
05.03.03.01 |
Entecavir Baraclude® |
|
15.01.02 |
Entonox® |
|
13.02.01 |
Epaderm® |
Cream
Ointment |
02.07.02 |
Ephedrine |
Intravenous injection |
12.02.02 |
Ephedrine |
Nasal drops
Licensed for over 12 years of age only |
07.04.04 |
Epirubicin |
Bladder instillation
Liaise with Pharmacy Aseptics for preparation of this product |
24.03 |
Epirubicin IV Injection |
|
02.02.03 |
Eplerenone |
Tablets
|
09.01.03 |
Epoetin alfa Eprex® |
Injection |
09.01.03 |
Epoetin beta NeoRecormon® |
Injection |
02.08.01 |
Epoprostenol Flolan® |
Infusion |
02.09 |
Eptifibatide Integrilin® |
Injection
Infusion
|
09.06.04 |
Ergocalciferol |
Oral solution
IM injection |
07.01.01 |
Ergometrine Maleate |
Injection |
07.01.01 |
Ergometrine Maleate and Oxytocin Syntometrine® |
Injection |
05.01.02.02 |
Ertapenem |
Intravenous Infusion
Not for inpatient use |
01.02 |
Erythromycin |
Tablets
Oral Suspension
Intravenous infusion
unlicensed indication |
05.01.05 |
Erythromycin |
Capsules
Tablets
Oral Suspension
Intravenous Infusion |
11.03.01 |
Erythromycin |
Eye ointment unlicensed special |
13.06.02 |
Erythromycin |
Tablets
First choice for rosacea. Alternative to oxytetracycline for acne. |
13.06.01 |
Erythromycin 2% Stiemycin® |
Topical solution |
13.06.01 |
Erythromycin 40mg with Zinc Acetate 12mg/mL Zineryt® |
Topical solution |
04.03.03 |
Escitalopram |
Tablets
Oral drops |
02.04 |
Esmolol |
Intravenous Infusion
Cardiologist/anaesthetist initiation only |
10.01.03 |
Etanercept Enbrel® |
Subcutaneous Injection
|
10.01.03 |
Etanercept Benepali® |
Subcutaneous Injection
|
13.05.03 |
Etanercept Enbrel® |
|
05.01.09 |
Ethambutol |
Tablets |
02.13 |
Ethanolamine Oleate |
Injection |
08.03.01 |
Ethinylestradiol |
Tablets |
04.08.01 |
Ethosuximide |
Capsules
Syrup |
10.01.01 |
Etodolac |
Capsules
Modified release tablets |
15.01.01 |
Etomidate Etomidate-Lipuro® |
|
15.01.01 |
Etomidate Hypnomidate® |
|
07.03.02.02 |
Etonorgestrel Nexplanon® |
Implant |
24.03 |
Etoposide IV Infusion |
|
24.03 |
Etoposide, Doxorubicin and Vincristine IV Infusion |
|
10.01.01 |
Etoricoxib Arcoxia® |
Tablets |
05.03.01 |
Etravirine Intelence® |
|
02.12 |
Evolocumab Repatha® |
Pre-filled syringe Pre-filled pen Only as per NICE TA394. Requires completion of Blueteq form prior to initiation. Available via Homecare providers.
|
06.04.01.01 |
Evorel Conti® |
Patches
Estradiol 50micrograms/24hours + norethisterone 170micrograms/24hours
|
06.04.01.01 |
Evorel Sequi® |
Patches
Estradiol 50micrograms
plus
Estradiol 50micrograms + norethisterone acetate 170micrograms |
06.04.01.01 |
Evorel® |
Patches
Estradiol 25, 50, 75, 100micrograms |
08.03.04.01 |
Exemestane |
Tablets
|
06.01.02.03 |
Exenatide Bydureon® prolonged-release |
Disposable pen
Once-weekly preparation |
02.12 |
Ezetimibe Ezetrol® |
Tablets
Not licensed for primary or secondary prevention of cardiovascular disease. |
10.01.04 |
Febuxostat Adenuric® |
Tablets
|
06.04.01.01 |
Femoston Conti® |
Tablets
Estradiol 1mg + dydrogesterone 5mg
|
06.04.01.01 |
Femoston® |
Tablets
Estradiol 1mg + dydrogesterone 10mg
Estradiol 2mg + dydrogesterone 10mg
|
02.12 |
Fenofibrate |
Capsules
Tablets
Fenofibrate has similar efficacy to bezafibrate in the reduction of triglycerides and is more potent in terms of LDL reduction and HDL elevation.
|
04.07.02 |
Fentanyl |
Patches
Buccal tablets (Effentora®) Palliative care only
Nasal spray (PecFent®) Palliative care only
|
15.01.04.03 |
Fentanyl |
|
09.01.01.02 |
Ferric Carboxymaltose Ferinject® |
Injection |
09.01.01.01 |
Ferric Maltol Feraccru® |
30mg iron per capsule
Consultant gastroenterologist only
Alternative to IV iron in IBD patients intolerant to existing oral iron products, as per GMMMMG recommendations |
09.01.01.01 |
Ferrous Fumarate |
45mg iron per 5ml |
09.01.01.01 |
Ferrous Fumarate |
68mg iron per tablet |
09.01.01.01 |
Ferrous Fumarate |
100mg iron per tablet |
09.01.01.01 |
Ferrous Sulphate |
65mg iron per tablet |
07.04.02 |
Fesoterodine |
M/R Tablets |
03.04.01 |
Fexofenadine |
Tablets
For established patients only |
06.01.01.01 |
Fiasp® Insulin Aspart |
3ml cartridge (via Novopen® devices) 3ml prefilled disposable pen (FlexTouch®)
As per GMMMG - for type 1 diabetics who:
- are planning or actively pregnant, or
- have post prandial glucose readings of >10mmol at 2 hours
|
05.01.07 |
Fidaxomicin Dificlir® |
Tablets
Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician |
09.01.06 |
Filgrastim Zarzio® |
Injection |
06.04.02 |
Finasteride |
Tablets |
02.03.02 |
Flecainide |
Tablets
Injection
Specialist initiation only.
Paediatric Use: Specialist initiation and secondary care management until stable. |
05.01.01.02 |
Flucloxacillin |
Capsules
Oral Solution
Injection |
24.01 |
Flucloxacillin IV Syringe |
500mg/10mL
1000mg/20mL
2000mg/40mL |
05.02.01 |
Fluconazole |
Capsules
Oral Suspension
Intravenous Infusion |
07.02.02 |
Fluconazole |
Capsule |
12.03.02 |
Fluconazole |
Capsules
|
05.02.05 |
Flucytosine Ancotil® |
Intravenous Infusion
ID consultant initiation only |
24.01 |
Flucytosine IV Infusion |
|
24.03 |
Fludarabine IV Infusion |
|
06.03.01 |
Fludrocortisone Acetate Florinef® |
Tablets |
13.04 |
Fludroxycortide Haelan® |
Cream
Ointment
Tape (for chronic localised recalcitrant dermatoses, but not acute or weeping) |
12.01.01 |
Flumetasone 0.02% with Clioquinol 1% Locorten-Vioform® |
Ear drops
|
12.01.01 |
Flumetasone 0.02% with Clioquinol 1% Locorten-Vioform® |
Ear drops
|
13.04 |
Fluocinolone Acetonide 0.0025% Synalar 1 in 10 Dilution® |
Cream |
13.04 |
Fluocinolone Acetonide 0.00625% Synalar 1 in 4 Dilution® |
Cream
Ointment |
13.04 |
Fluocinolone Acetonide 0.025% Synalar® |
Cream
Gel
Ointment |
13.04 |
Fluocinolone Acetonide 0.025% with Clioquinol 3% Synalar C® |
Cream
Ointment |
13.04 |
Fluocinolone Acetonide 0.025% with Neomycin Sulphate 0.5% Synalar N® |
Cream
Ointment |
11.04.01 |
Fluocinolone intravitreal implant Iluvien® |
Intravitreal implant
Specialist use only |
13.04 |
Fluocinonide 0.05% Metosyn® |
FAPG cream
Dermatology only |
11.08.02 |
Fluorescein Sodium Minims® |
Single-use eye drops
Also available with local anaesthetic - see section 11.7 |
11.04.01 |
Fluorometholone FML® |
Eye drops
Intra-ocular penetration is poor. It may be considered useful in a few patients with chronic low grade uveitis where raised intra-ocular pressure has been problematic. |
11.99.99.99 |
Fluorouracil |
Subconjunctival injection
Prepared by pharmacy aseptics unit for named-patient use. |
13.08.01 |
Fluorouracil 0.5%, Salicylic Acid 10% Actikerall® |
Solution
Dermatology only |
24.03 |
Fluorouracil Ophthalmic |
|
04.03.03 |
Fluoxetine |
Capsules
Liquid |
04.02.01 |
Flupentixol |
Tablets |
04.03.04 |
Flupentixol |
|
04.02.02 |
Flupentixol Decanoate Depixol® |
|
04.02.02 |
Fluphenazine Decanoate Modecate® |
|
03.02 |
Fluticasone |
Metered dose inhaler (Flixotide® Evohaler)
Dry powder inhaler (Flixotide® Accuhaler)
Nebules |
03.02 |
Fluticasone / umeclidinium / vilanterol Trelegy Ellipta® |
Dry powder inhaler (DPI)
Combination ICS/LABA/LAMA inhaler |
03.02 |
Fluticasone and formoterol Flutiform® |
Metered dose inhaler
Combination ICS/LABA inhaler
Licensed for ASTHMA only. |
03.02 |
Fluticasone and salmeterol Sirdupla® |
Metered dose inhaler
Combination ICS/LABA inhaler
Only licensed for use in asthma |
03.02 |
Fluticasone and salmeterol AirFluSal® |
Dry powder inhaler (Forspiro®)
Combination ICS/LABA inhaler
|
03.02 |
Fluticasone furoate & vilanterol Relvar Ellipta® |
Dry powder inhaler
Combination ICS/LABA inhaler
184/22 strength licensed for ASTHMA only |
12.02.01 |
Fluticasone Propionate |
50mcg/metered dose Nasal Spray |
04.03.03 |
Fluvoxamine Maleate |
Tablets |
09.01.02 |
Folic Acid |
Tablets
Oral syrup
Injection (unlicensed) |
02.08.01 |
Fondaparinux Arixtra® |
FIRST CHOICE FOR ACUTE CORONARY SYNDROME ONLY
Subcutaneous injection
Depends on indication - see GMMMG website for further details
Approved for:
- Treatment of acute coronary syndromes (from 4th Feb 2019)
- Prevention of venous thromboembolic events in orthopaedic surgery
Awaiting Trust-approved protocols for other indications. |
09.06.07 |
Forceval® |
Capsules
Soluble Tablets |
03.01.01.01 |
Formoterol |
Dry powder inhaler 12 micrograms/dose (Easyhaler®)
Dry powder inhaler 6 micrograms/dose, 12 micrograms/dose (Oxis® Turbohaler)
|
05.03.01 |
Fosamprenavir Telzir® |
|
24.03 |
Foscarnet IV Infusion |
|
05.03.02.02 |
Foscarnet Sodium Foscavir® |
|
05.01.13 |
Fosfomycin |
Granules for oral suspension
Injection
Injection - Microbiology / ID recommendation only; for the treatment of carbapenemase-producing enterobacteriaceae
|
08.03.04.01 |
Fulvestrant Faslodex® |
Intramuscular injection
Red for new patients. Not recommended by NICE.
|
02.02.02 |
Furosemide |
Tablets
Liquid
Injection
|
11.03.01 |
Fusidic Acid |
Eye drops |
13.10.01.02 |
Fusidic Acid 2% Fucidin® |
Cream
Ointment |
04.07.03 |
Gabapentin |
Capsules
Oral solution |
04.07.03 |
Gabapentin |
Capsules
Oral solution |
04.08.01 |
Gabapentin |
Capsules
Oral solution |
06.01.05 |
Gabapentin |
Capsules
Oral solution |
04.11 |
Galantamine |
Tablets
M/R capsules
Oral solution
Commissioning arrangements may vary and in some localities this is Green2 - check with relevant CCG |
05.03.02.02 |
Ganciclovir Cymevene® |
Prepared by pharmacy aseptics during working hours. Liaise with pharmacy. |
11.03.03 |
Ganciclovir |
Eye gel
Specialist ophthalmologist only |
24.03 |
Ganciclovir IV Infusion |
|
24.03 |
Ganciclovir IV Infusion |
|
01.01.02 |
Gaviscon Advance |
Suspension
Chewable tablets |
01.01.02 |
Gaviscon Infant |
Oral powder |
09.02.02.02 |
Gelatin Gelofusine® |
May be supplied as an alternative to Gelaspan if unavailable |
09.02.02.02 |
Gelatin Gelaspan® |
|
12.03.01 |
Gelclair® |
Sachets |
24.03 |
Gemcitabine IV Infusion |
|
07.01.01 |
Gemeprost |
Pessaries |
24.03 |
Gemtuzumab IV Infusion |
|
05.01.04 |
Gentamicin |
Injection
|
11.03.01 |
Gentamicin Genticin® |
0.3% eye/ear drops
1.5% eye drops unlicensed special
|
12.01.01 |
Gentamicin Genticin® |
Ear/eye drops
Not on GMMMG formulary |
12.03.05 |
Glandosane® |
Aerosol spray |
06.01.02.01 |
Gliclazide |
Tablets
|
06.01.02.01 |
Glimepiride |
Tablets |
06.01.02.01 |
Glipizide |
Tablets |
06.01.04 |
Glucagon GlucaGen® HypoKit |
|
06.01.04 |
GlucoGel® |
|
09.02.02.01 |
Glucose 10% Intravenous |
500ml bag
1L bag
|
09.02.02.01 |
Glucose 15% Intravenous |
500ml bag |
09.02.02.01 |
Glucose 20% Intravenous |
500ml bag |
09.02.02.01 |
Glucose 5% Intravenous |
50ml bag
100ml bag
250ml bag
500ml bag
500ml Polyfusor
1L bag
|
09.02.02.01 |
Glucose 50% Intravenous |
20ml amps
50ml vial
500ml bag |
01.06.02 |
Glycerol (Glycerin) |
Suppositories (1st line for rectal use) |
02.06.01 |
Glyceryl Trinitrate |
Spray
Sublingual Tablets
Patches
Injection
|
01.07.04 |
Glyceryl Trinitrate 0.4% Ointment Rectogesic® |
|
07.04.04 |
Glycine 1.5% |
Bladder irrigation solution |
03.01.02 |
Glycopyrronium Seebri breezhaler® |
Inhalation powder, hard capsule for use with Breezhaler® device
Reserved for COPD patients with intolerance to tiotropium, or those who cannot use tiotropium devices. |
15.01.03 |
Glycopyrronium |
|
03.01.04 |
Glycopyrronium / Indacaterol Ultibro® Breezhaler |
Combination LABA/LAMA inhaler |
13.12 |
Glycopyrronium bromide |
Dermatology only |
10.01.03 |
Golimumab |
Subcutaneous Injection
|
06.07.02 |
Goserelin |
Intradermal implant 3.6mg (every 28 days)
For use in breast and prostate cancer, see sections 8.3.4.1 and 8.3.4.2.
"Amber" for licensed indications, "Red" for all unlicensed uses. |
08.03.04.02 |
Goserelin Zoladex® |
Zoladex® implant
Zoladex®LA implant
For licensed indications
|
02.05.03 |
Guanethidine Monosulphate Ismelin® |
Intramuscular injection
Licensed for rapid control of blood pressure, however alternative agents are preferred (BNF).
|
04.04 |
Guanfacine Intuniv® |
Prolonged-release tablets |
14.04 |
Haemophilus influenzae type B Combined Vaccine Menitorix® |
|
04.02.01 |
Haloperidol |
Tablets
Capsules
Oral liquid
Injection |
04.02.02 |
Haloperidol Haldol Decanoate® |
|
04.06 |
Haloperidol |
Tablets Capsules Oral liquid Injection |
02.08.01 |
Heparin |
Flush solution
For maintaining patency of peripheral venous catheters, sodium chloride injection 0.9% is as effective as heparin flushes. The role of heparin flushes in maintaining patency of arterial and central venous catheters is unclear (BNF).
All flush solutions must be prescribed. See NPSA Rapid Response Alert. |
02.08.01 |
Heparin |
Injection
|
24.01 |
Heparin 50 units in 50mL 0.18% sodium chloride |
|
13.13 |
Heparinoid 0.3% Hirudoid® |
Cream |
14.04 |
Hepatitis A vaccine Single Component Havrix® |
|
14.04 |
Hepatitis A vaccine with Hepatitis B vaccine Twinrix® |
|
14.04 |
Hepatitis A vaccine with typhoid vaccine Hepatyrix® |
|
14.04 |
Hepatitis A vaccine with typhoid vaccine VIATIM® |
|
14.05.02 |
Hepatitis B immunoglobulin |
Medical team to contact Clinical Virology at Central Manchester Foundation Trust (0161 276 8853) |
14.04 |
Hepatitis B vaccine Single Component Engerix B® |
|
14.04 |
Hepatitis B vaccine Single Component Fendrix® |
Approved by Medical D&T on 26/3/15 for use after failure of previous vaccination course, as per BHIVA guidelines. |
14.04 |
Hepatitis B vaccine Single Component HBvaxPRO® |
|
13.11.02 |
Hibiscrub® Chlorhexidine |
|
13.11.02 |
Hibitane Obstetric® |
Cream |
06.01.01.01 |
Humalog® Insulin Lispro |
3ml cartridge (via Autopen® Classic or HumaPen®)
3ml prefilled disposable pen (Kwikpen®)
|
06.01.01.02 |
Humalog® Mix25 Biphasic Insulin Lispro |
3ml cartridge (via Humapen® Luxura device)
3ml prefilled disposable pen (Kwikpen® )
|
06.01.01.02 |
Humalog® Mix50 Biphasic Insulin Lispro |
3ml cartridge (via Humapen® Luxura device)
3ml disposable prefilled pen (Kwikpen®)
|
09.02.02.02 |
Human Albumin Solution |
This is a BLOOD product. Obtain from haematology (not pharmacy). |
06.05.01 |
Human Menopausal Gonadotrophins Menopur® |
Injection |
14.04 |
Human papilloma virus vaccine Gardasil® |
|
06.01.01.02 |
Humulin® I Isophane Insulin |
3ml cartridge (via Humapen® Luxura device)
3ml prefilled disposable pen (Kwikpen®)
|
06.01.01.02 |
Humulin® M3 Biphasic Isophane Insulin |
3ml cartridge (via Humapen® Luxura device)
3ml prefilled disposable pen (Kwikpen®)
|
06.01.01.01 |
Humulin® S |
3ml cartridge
10ml vial |
10.01 |
Hyaluronic acid |
See link |
10.03.01 |
Hyaluronidase |
Injection |
02.05.01 |
Hydralazine |
Tablets
Injection
Oral hydralazine may be used in combination with long-acting nitrates in patients with heart failure who are still symptomatic despite optimal therapy with ACE inhibitor and beta blocker or when ACE inhibitors and ARBs are contra-indicated or not tolerated.
Not to be used as monotherapy (causes tachycardia and fluid retention). (BNF)
|
01.05.02 |
Hydrocortisone |
Rectal foam
Injection |
06.03.02 |
Hydrocortisone |
Tablets
Injection (as sodium phosphate)
Injection (as sodium succinate)
|
12.03.01 |
Hydrocortisone Corlan® |
Oromucosal tablets |
13.04 |
Hydrocortisone |
Cream (0.5%, 1%, 2.5%)
Ointment (0.5%, 1%, 2.5%)
|
13.04 |
Hydrocortisone 0.5% with Nystatin and Chlorhexidine Nystaform-HC® |
Cream
Ointment |
13.04 |
Hydrocortisone 0.5% with Nystatin, Benzalkonium and Dimeticone Timodine® |
Cream |
13.04 |
Hydrocortisone 1% with Clotrimazole 1% Canesten HC® |
Cream |
13.04 |
Hydrocortisone 1% with Miconazole Nitrate 2% Daktacort® |
Cream
Ointment |
13.04 |
Hydrocortisone 1%, Urea 10% and Lactic Acid 5% Calmurid HC® |
Cream |
10.01.02.02 |
Hydrocortisone acetate Hydrocortistab® |
25mg/ml intra-articular injection |
13.04 |
Hydrocortisone Acetate 1% with Fusidic Acid 2% Fucidin H® |
Cream
|
12.01.01 |
Hydrocortisone Acetate 1% with Gentamicin 0.3% Gentisone® HC |
Ear drops
|
13.04 |
Hydrocortisone Butyrate 0.1% Locoid® |
Cream
Ointment |
11.04.01 |
Hydrocortisone sodium phosphate Softacort® |
Unit-dose eye drops (3.35mg/mL)
Preservative free |
12.01.01 |
Hydrocortisone with Antibactrial Otosporin® |
Ear drops |
12.03.04 |
Hydrogen Peroxide |
Mouthwash |
13.11.06 |
Hydrogen Peroxide Solution BP |
|
13.02.01.01 |
Hydromol® bath and shower emollient |
|
13.02.01 |
Hydromol® ointment |
Ointment |
09.01.02 |
Hydroxocobalamin |
Injection |
08.01.05 |
Hydroxycarbamide Hydrea® |
for essential thrombocythaemia, myelofibrosis or polycythaemia with high risk of complications
for chemotherapy
|
10.01.03 |
Hydroxychloroquine |
Tablets |
03.04.01 |
Hydroxyzine |
Tablets
Oral Solution
Hydroxyzine is favoured by dermatologists for its anti-itch and sedating effects.
|
10.01 |
Hylan G-F 20 Synvisc® |
See link |
01.02 |
Hyoscine Butylbromide Buscopan® |
Tablets
Injection |
04.06 |
Hyoscine Hydrobromide |
Tablets Patches |
04.06 |
Hyoscine Hydrobromide |
Tablets
Patch |
15.01.03 |
Hyoscine Hydrobromide |
|
03.07 |
Hypertonic sodium chloride |
Nebuliser solution |
11.08.01 |
Hypromellose |
0.3% eye drops
0.5% eye drops
|
06.01.01.02 |
Hypurin® Bovine Isophane Isophane Insulin |
3ml cartridges (via Autopen® Classic)
• Some long-standing type 1 diabetic patients may be on animal insulin.
• Patients need not be transferred to human insulin unless clinical need dictates
• Human insulin and analogues should be used in preference to animal insulin
|
06.01.01.01 |
Hypurin® Bovine Neutral |
3ml cartridge (for Autopen® Classic)
• Some long-standing type 1 diabetic patients may be on animal insulin.
• Patients need not be transferred to human insulin unless clinical need dictates
• Human insulin and analogues should be used in preference to animal insulin |
06.01.01.02 |
Hypurin® Porcine 30/70 Mix Biphasic Isophane Insulin |
3ml cartridge (for Autopen® Classic)
• Some long-standing type 1 diabetic patients may be on animal insulin.
• Patients need not be transferred to human insulin unless clinical need dictates
• Human insulin and analogues should be used in preference to animal insulin
|
06.01.01.02 |
Hypurin® Porcine Isophane Isophane Insulin |
3ml cartridge (via Autopen® Classic)
• Some long-standing type 1 diabetic patients may be on animal insulin.
• Patients need not be transferred to human insulin unless clinical need dictates
• Human insulin and analogues should be used in preference to animal insulin
|
06.01.01.01 |
Hypurin® Porcine Neutral |
3ml cartridge (for Autopen® Classic)
• Some long-standing type 1 diabetic patients may be on animal insulin.
• Patients need not be transferred to human insulin unless clinical need dictates
• Human insulin and analogues should be used in preference to animal insulin |
06.01.01.02 |
Hypurin®Bovine Lente Insulin Zinc suspension |
10ml vial
• Some long-standing type 1 diabetic patients may be on animal insulin.
• Patients need not be transferred to human insulin unless clinical need dictates
• Human insulin and analogues should be used in preference to animal insulin
|
06.06.02 |
Ibandronic Acid Bondronat® |
50mg Tablets
Concentrate for infusion
Approved for reduction of bone damage in bone metastases in advanced breast cancer
|
07.01.01.01 |
Ibuprofen Pedea® |
Intravenous solution |
10.01.01 |
Ibuprofen |
Tablets
Oral suspension
5% gel |
10.03.02 |
Ibuprofen gel |
Gel |
24.03 |
Idarubicin IV Infusion |
|
24.03 |
Ifosfamide and Mesna IV Infusion |
|
02.05.01 |
Iloprost |
Injection
unlicensed
For use in rheumatology patients, see attached guidelines. |
04.03.01 |
Imipramine |
Tablets
Oral solution |
04.07.03 |
Imipramine |
Tablets
Oral solution |
07.04.02 |
Imipramine |
Tablets
Oral solution |
13.07 |
Imiquimod Aldara® |
5% Cream |
14.04 |
Inactivated Influenza Vaccine (Split Virion) |
|
03.01.01.01 |
Indacaterol |
Dry powder inhaler 150 microgram/dose, 300 microgram/dose (Onbrez Breezhaler®)
May be considered as a treatment option for COPD patients in whom another long acting β-adrenoceptor agonist (LABA) would be suitable (GMMMG).
Not licensed for asthma. |
02.02.01 |
Indapamide |
Tablets
First choice for hypertension, where a thiazide is indicated (see NICE CG127: Hypertension).
N.B. Modified release tablets are NON-formulary |
11.08.02 |
Indocyanine green |
unlicensed
|
07.01.01.01 |
Indometacin |
Injection |
07.01.03 |
Indometacin |
Suppositories Capsules
Unlicensed indication |
10.01.01 |
Indometacin |
Capsules
Modified-release capsules
Suppositories
|
13.11.01 |
Industrial Methylated Spirit BP |
|
09.04 |
Infatrini Peptisorb |
Dose dependent on age |
01.05.03 |
Infliximab Remsima® |
For new patients only |
01.05.03 |
Infliximab Inflectra® |
|
01.05.03 |
Infliximab Remicade® |
|
10.01.03 |
Infliximab |
Intravenous Infusion |
13.05.03 |
Infliximab Remicade® |
|
24.03 |
Infliximab IV Infusion Inflectra |
|
24.03 |
Infliximab IV Infusion Remsima |
Outsourced product - not prepared by PAT Aseptic Services |
24.03 |
Infliximab IV Infusion Remicade |
|
13.08.01 |
Ingenol mebutate Picato® |
Gel
Dermatology Only |
06.01.01.02 |
Insulatard® Isophane Insulin |
3ml cartridge (via Novopen®4)
3ml prefilled disposable pen (Innolet®)
|
06.01.01.02 |
Insuman® Basal Isophane Insulin |
3ml cartridge (via ClikSTAR® or Autopen®24 devices)
3ml prefilled disposable pen (Solostar®)
|
06.01.01.02 |
Insuman® Comb 15 Biphasic Isophane Insulin |
3ml cartridge (via ClikSTAR® or Autopen®24 devices)
|
06.01.01.02 |
Insuman® Comb 25 Biphasic Isophane Insulin |
3ml cartridge (via ClikSTAR® or Autopen®24 devices)
3ml prefilled disposable pen (Solostar®)
|
06.01.01.02 |
Insuman® Comb 50 Biphasic Isophane Insulin |
3ml cartridge (via ClikSTAR® or Autopen®24 devices)
|
06.01.01.01 |
Insuman® Rapid |
3ml cartridge (via ClikSTAR® or Autopen® 24)
|
08.02.04 |
Interferon Alfa-2b IntronA® |
|
08.02.04 |
Interferon Alfa-2b Roferon-A® |
|
07.03.04 |
Intra-uterine Contraceptive Devices TT 380 Slimline® |
|
07.03.02.03 |
Intra-uterine Progestogen Only System Mirena® |
|
03.01.02 |
Ipratropium |
Metered dose inhaler (MDI) 20 micrograms/dose
Nebuliser solution 250 micrograms/ml, 500 micrograms/ml
|
12.02.02 |
Ipratropium Bromide Rinatec® |
|
02.05.05.02 |
Irbesartan |
Tablets
GMMMG endorse use for renal patients. |
09.01.01.02 |
Iron Dextran CosmoFer® |
Injection
|
09.01.01.02 |
Iron Isomaltoside Monofer® |
Injection
|
09.01.01.02 |
Iron Sucrose Venofer® |
Injection |
15.01.02 |
Isoflurane |
|
05.01.09 |
Isoniazid |
Tablets
Injection |
02.07.01 |
Isoprenaline |
Concentrate for injection or infusion (dilute before use).
unlicensed
|
02.06.01 |
Isosorbide Dinitrate |
Injection
|
02.06.01 |
Isosorbide Mononitrate |
Modified release tablets
Tablets
|
13.06.02 |
Isotretinoin Roaccutane® |
Capsules
Dermatology only |
01.06.01 |
Ispaghula Husk |
Granules |
05.02.01 |
Itraconazole |
Capsules
Oral Liquid
Intravenous Infusion
Itraconazole is associated with liver damage and should no be given to patients with a history of liver disease.
Following reports of heart failure, caution is advised when prescribing itraconazole to patients at high risk of heart failure (BNF).
|
02.06.03 |
Ivabradine |
Tablets
Specialist initiation
Ivabradine should only be initiated in people with NYHA class II to IV stable chronic heart failure with systolic dysfunction who:
are in sinus rhythm with a heart rate of 75 bpm or more
have a left ventricular ejection fraction of 35% or less, AND
who have been stable for 4 weeks on optimised standard therapy with ACE inhibitors, beta-blockers and aldosterone antagonists (or when beta-blockers are contra-indicated or not tolerated). |
05.05.06 |
Ivermectin |
Tablets
unlicensed
|
05.05.07 |
Ivermectin |
Tablets
unlicensed
|
05.05.08 |
Ivermectin |
Tablets
unlicensed
|
13.10.04 |
Ivermectin |
Tablets
unlicensed
|
14.04 |
Japanese Encephalitis Vaccine Ixiaro® |
NMGH Travel Clinic only |
09.04.02 |
Jevity |
500ml 1000ml 1500ml
|
09.04.02 |
Jevity 1.5kcal |
500ml 1000ml 1500ml
|
09.04.02 |
Jevity PLUS |
500ml 1000ml 1500ml
|
09.04.02 |
Jevity PLUS HP |
|
09.04.02 |
Jevity Promote |
|
04.07.03 |
Ketamine oral solution |
Specialist initiation by pain team or palliative care only Unlicensed |
07.02.02 |
Ketoconazole 2% |
Cream |
13.10.02 |
Ketoconazole 2% Cream Nizoral® |
Cream |
13.09 |
Ketoconazole 2% Shampoo |
Shampoo |
10.03.02 |
Ketoprofen gel |
Gel |
11.08.02 |
Ketorolac Acular® |
Eye drops
Ophthalmic specialist initiation only |
15.01.04.02 |
Ketorolac Toradol® |
|
09.06.07 |
Ketovite® |
Tablets
Liquid |
01.06.05 |
Klean-Prep® |
|
06.04.01.01 |
Kliofem® |
Tablets
Estradiol 2mg + norethisterone acetate 1mg |
06.04.01.01 |
Kliovance® |
Tablets
Estradiol 1mg + norethisterone acetate 500micrograms |
02.04 |
Labetalol |
Tablets
Injection
Infusion
Labetalol is a first line option for the management of hypertension in pregnancy (see NICE Guidance - Hypertension in Pregnancy). |
04.08.01 |
Lacosamide |
Tablets Syrup
Solution for infusion |
01.06.04 |
Lactulose Solution |
Lactulose takes up to 48 hours to work but is often inappropriately used “when required”. It is unpleasant to take and compliance may be a problem. Its main clinical benefit is in the management of hepatic encephalopathy. |
05.03.01 |
Lamivudine |
Tablets
Oral Solution |
05.03.03.01 |
Lamivudine |
Tablets
Oral Solution |
04.08.01 |
Lamotrigine |
Tablets
Dispersible tablets |
08.03.04.03 |
Lanreotide Somatuline® |
Injection (Somatuline® LA and Somatuline® Autogel)
|
01.03.05 |
Lansoprazole |
Capsules
Orodispersible tablets - first choice for patients with enteral feeding tubes |
09.05.02.02 |
Lanthanum Fosrenol ® |
Tablets
|
06.01.01.02 |
Lantus® Insulin Glargine |
3ml cartridge (via ClikSTAR® or Autopen®24 devices)
3ml prefilled disposable pen (Solostar®)
|
11.06 |
Latanoprost |
Eye drops
Single-use eye drops |
11.06 |
Latanoprost 0.005% with Timolol 0.5% |
Eye drops
Combination products are licensed for once daily use where prostaglandin analogue alone is not adequate. Only use where patient has difficulty with compliance/administration. |
05.03.03.02 |
Ledipasvir/Sofosbuvir Harvoni® 90mg/400mg |
Tablets
Requires MDT discussion with ID team |
10.01.03 |
Leflunomide |
Tablets
Specialist Initiation Only |
08.02.04 |
Lenalidomide Revlimid® |
Capsules |
09.01.06 |
Lenograstim Granocyte® |
Injection |
02.06.02 |
Lercanidipine |
Tablets
|
08.03.04.01 |
Letrozole |
Tablets
|
06.07.02 |
Leuprorelin Prostap® |
Prefilled dual chamber syringe
3.75mg (monthly)
11.25mg (every 3 months)
For use in prostate cancer, see section 8.3.4.2.
"Amber" for licensed indications, "Red" for all unlicensed uses. |
08.03.04.02 |
Leuprorelin Acetate Prostap® |
Prostap®3 DCS 11.25mg injection
Prostap® SR DCS 3.75mg injection
1st choice for prostate cancer
For licensed indications
|
05.05.02 |
LEVAMISOLE Tablets 50 mg |
Tablets
unlicensed |
06.01.01.02 |
Levemir® Insulin Detemir |
3ml cartridges (via Novopen®4 device)
3ml prefilled disposable pen (Flexpen® or Innolet®) |
04.08.01 |
Levetiracetam Keppra® |
Tablets
Oral solution
Intravenous infusion |
11.06 |
Levobunolol |
Eye drops
Unit dose eye drops |
15.02 |
Levobupivacaine Chirocaine® |
|
05.01.12 |
Levofloxacin |
Tablets
Intravenous Infusion |
11.03.01 |
Levofloxacin |
Eye drops
Unit dose eye drops |
13.03 |
Levomenthol Dermacool® |
Cream |
04.02.01 |
Levomepromazine |
Tablets
Injection |
04.06 |
Levomepromazine |
Tablets Injection
In the last days of life, levomepromazine is used as a first-line antiemetic. |
04.06 |
Levomepromazine |
Tablets
Injection |
07.03.05 |
Levonorgestrel Levonelle® 1500 |
|
06.02.01 |
Levothyroxine |
Tablets
Oral liquid |
12.03.01 |
Lidocaine |
10% mouth spray
5% ointment |
15.02 |
Lidocaine |
|
01.07.01 |
Lidocaine 5% |
Ointment |
11.07 |
Lidocaine Hydrochloride 4% with Fluorescein 0.25% Minims® |
Single-use eye drops |
01.06.07 |
Linaclotide Constella® |
Capsules
Gastroenterologists only |
06.01.02.03 |
Linagliptin Trajenta® |
Tablets
First choice 'Gliptin' for patients with moderate or severe renal impairment (CrCl<50ml/min, eGFR<59ml/min)
|
05.01.07 |
Linezolid |
Tablets
Suspension
Intravenous Infusion
Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician |
06.02.01 |
Liothyronine |
Tablets
For patients who, in exceptional circumstances, have an on-going need for liothyronine as confirmed by a consultant endocrinologist
For patients with thyroid cancer prior to radioiodine treatment
Injection
For acutely unwell patients with profound hypothyroidism
|
13.02.01 |
Lipobase® |
Cream
Dermatology only |
13.02.01 |
Liquid and White Soft Paraffin Ointment (50:50) |
Ointment |
11.08.01 |
Liquid Paraffin Lacri-Lube® |
Eye ointment |
11.08.01 |
Liquid Paraffin and Vitamin A Hylo-Night® |
Eye ointment |
06.01.02.03 |
Liraglutide Victoza® |
Disposable pen |
04.04 |
Lisdexamfetamine Elvanse® |
Capsules
Pennine Care: Use may be considered second or third line when treatment with methylphenidate m/r not successful and patient has swallowing difficulties (as atomoxetine caps cannot be opened) and where drug diversion is not a risk. |
02.05.05.01 |
Lisinopril |
Tablets |
04.02.03 |
Lithium Carbonate tablets Camcolit® or Priadel® |
|
04.02.03 |
Lithium Citrate liquid Li-Liquid® or Priadel® |
|
06.01.02.03 |
Lixisenatide Lyxumia® |
Disposable pen |
11.04.02 |
Lodoxamide Alomide® |
Eye drops |
07.03.01 |
Loestrin 20® Ethinylestradiol 20 mcg / norethisterone 1mg |
Low strength preparation |
04.03.01 |
Lofepramine |
Tablets
Oral suspension |
04.10.03 |
Lofexidine Hydrochloride |
Specialist initiation only |
07.03.01 |
Logynon® Ethinylestradiol / levonorgestrel phased pill |
Tri-phasic preparation |
01.04.02 |
Loperamide |
Capsules
Syrup |
05.03.01 |
Lopinavir and Ritonavir Kaletra® |
|
03.04.01 |
Loratadine |
Tablets
Oral Solution |
04.01.02 |
Lorazepam |
Tablets
Injection |
15.01.04.01 |
Lorazepam |
|
04.08.02 |
Lorazepam Injection |
|
02.05.05.02 |
Losartan |
Tablets
|
05.01.03 |
Lymecycline |
Capsules |
13.06.02 |
Lymecycline |
Capsules
To be initiated by Dermatology only
Alternative choice for acne only |
01.06.04 |
Macrogol Movicol® sachet |
|
09.05.01.03 |
Magnesium Aspartate Magnaspartate® |
Sachets
|
09.05.01.03 |
Magnesium Sulphate |
50% Injection
10% Injection
1 gram Mg = 4 mmol Mg.
|
13.10.05 |
Magnesium Sulphate Paste BP |
Paste |
01.01.01 |
Magnesium Trisilicate Mixture BP |
|
13.10.04 |
Malathion 0.5% Derbac-M® |
Liquid |
13.10.04 |
Malathion 0.5% Derbac-M® |
Liquid |
02.02.05 |
Mannitol |
Intravenous Infusion |
05.03.01 |
Maraviroc |
|
14.04 |
Measles, Mumps and Rubella Vaccine, Live (MMR) |
|
05.05.01 |
Mebendazole |
Chewable tablets
Oral suspension |
05.05.04 |
Mebendazole |
See section 5.5.1 |
01.02 |
Mebeverine Hydrochloride |
Tablets
Oral suspension |
06.04.01.02 |
Medroxyprogesterone Acetate |
Tablets |
07.03.02.02 |
Medroxyprogesterone Acetate Depo-Provera® |
12-weekly IM injection |
08.03.02 |
Medroxyprogesterone Acetate Provera® |
Tablets |
10.01.01 |
Mefenamic Acid |
Capsules
Tablets
Oral suspension |
05.04.01 |
Mefloquine |
Tablets |
08.03.02 |
Megestrol Acetate Megace® |
Tablets |
04.01.01 |
Melatonin |
M/R tablets
Capsules (unlicensed)
Tablets (unlicensed)
Oral liquid (unlicensed)
applies when licensed product used in adult patients over 55
The licensed M/R tablets can be crushed for administration in dysphagia or via enteral feeding tubes if necessary. This obviously means that they would no longer be 'modified release'. |
10.01.01 |
Meloxicam |
Tablets |
04.11 |
Memantine |
Tablets
Oral solution
Commissioning arrangements may vary and in some localities this is Green2 - check with relevant CCG |
09.06.06 |
Menadiol Sodium Phosphate |
Tablets
Water-soluble. For use in patients with fat malabsorption syndromes, e.g. biliary obstruction or hepatic disease (BNF) |
14.04 |
Meningococcal group B Vaccine Bexsero® |
|
14.04 |
Meningococcal group C conjugate vaccine NeisVac-C® |
|
14.04 |
Meningococcal polysaccharide A, C, W135 and Y vaccine Nimenrix® or Menveo® |
|
03.04.02 |
Mepolizumab Nucala® |
Subcutaneous injection |
01.05.03 |
Mercaptopurine |
Tablets |
05.01.02.02 |
Meropenem |
Injection
Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician |
01.05.01 |
Mesalazine Mezavant® XL |
Tablets
Specialist initiation only
For when symptoms are not controlled with 400mg or 800mg preparations or when concordance is an issue.
|
01.05.01 |
Mesalazine Asacol® |
Tablets
Foam enema
Suppositories |
01.05.01 |
Mesalazine Pentasa® |
Tablets
Granules
Retention enema
Suppositories
Tablets may be dispersed in water for patients with dysphagia / enteral feeding tubes
|
01.05.01 |
Mesalazine Salofalk® |
Granules
Granules may be used for patients with swallowing difficulties. Tablets are NON FORMULARY |
01.05.01 |
Mesalazine Octasa® |
Tablets |
08.01 |
Mesna |
Tablets
Injection |
24.01 |
Mesna IV Infusion |
|
13.02.02 |
Metanium® |
Ointment |
02.07.02 |
Metaraminol |
Injection
unlicensed |
06.01.02.02 |
Metformin |
Tablets
Oral Solution
Green3 when used in pregnancy or PCOS
|
06.01.02.02 |
Metformin Hydrochloride Modified Release |
MR Tablets
Metformin MR should only be used where the standard metformin tablets have been tried and are not tolerated due to GI problems. Any new prescription of the MR preparation should be reviewed soon after initiation (recommend checking HbA1c after 3 months and assess patient for adherence to treatment/adverse effects), discontinue if not tolerated or ineffective. |
04.10.03 |
Methadone |
Solution
Injection |
10.01.03 |
Methotrexate |
Tablets
Pre-filled injection pen (supplied to patients via homecare arrangements)
Specialist initiation only
WEEKLY dosing
|
13.05.03 |
Methotrexate |
Tablets
Injection |
01.05.03 |
Methotrexate - injection |
|
01.05.03 |
Methotrexate - oral |
Tablets
|
24.03 |
Methotrexate IM Injection |
|
24.03 |
Methotrexate Intrathecal Injection |
|
24.03 |
Methotrexate IV Infusion |
|
13.05.02 |
Methoxypsoralen |
Tablets
Dermatology only |
01.06.01 |
Methycellulose Celevac® |
Tablets |
13.08.01 |
Methyl-5-Aminolevulinate Metvix® |
Cream
Dermatology Only |
02.05.02 |
Methyldopa |
Tablets
Used in the management of hypertension in pregnancy |
04.04 |
Methylphenidate |
Tablets M/R tablets or capsules |
06.03.02 |
Methylprednisolone |
Injection
Depot injection
Tablets |
10.01.02.02 |
Methylprednisolone Acetate Depo-Medrone® |
Injection |
10.01.02.02 |
Methylprednisolone Acetate Depo-Medrone® with Lidocaine |
Injection |
01.02 |
Metoclopramide |
Tablets
Oral solution
Injection
Should only be prescribed for short-term use (up to 5 days). For adults, the maximum dose in 24 hours is 30mg. |
04.06 |
Metoclopramide |
Tablets
Oral solution
Injection |
04.06 |
Metoclopramide |
Tablets Oral solution Injection |
04.06 |
Metoclopramide |
Tablets Suspension Injection |
02.02.01 |
Metolazone |
Tablets
unlicensed
UK licensed product discontinued in 2012. Unlicensed import product is available from Pharmacy.
|
02.04 |
Metoprolol |
Tablets (not a preferred GMMMG option)
Injection
|
05.01.11 |
Metronidazole |
Tablets
Oral suspension
Suppositories
Intravenous Infusion
|
05.04.02 |
Metronidazole |
See section 5.1.11 |
07.02.02 |
Metronidazole |
Vaginal gel |
13.10.01.02 |
Metronidazole gel |
Gel |
06.07.03 |
Metyrapone Metopirone® |
Capsules
For specialist use only |
02.03.02 |
Mexiletine |
|
02.03.02 |
Mexiletine |
unlicensed
Cardiology consultant only
Unlicensed import |
04.03.01 |
Mianserin |
|
07.02.02 |
Miconazole |
Cream |
12.03.02 |
Miconazole Daktarin® |
Oral Gel |
13.10.02 |
Miconazole 2% Cream |
Cream |
07.03.01 |
Microgynon 30 ED® Ethinylestradiol 30 mcg / levonorgestrel 150 mcg |
Standard strength, everyday preparation |
07.03.01 |
Microgynon 30® or Levest® Ethinylestradiol 30mcg / levonorgestrel 150mcg |
Standard strength preparation |
07.03.02 |
Micronor® Norethisterone 350mcg |
|
15.01.04.01 |
Midazolam Hypnovel® |
|
04.08.02 |
Midazolam Buccal Solution Buccolam® |
Paediatric use only |
02.07 |
Midodrine |
Tablets
For hypotensive states. Not to be initiated in primary care.
|
07.01.02 |
Mifepristone Mifegyne® |
Tablets |
04.07.04.01 |
Migraleve® |
"Pink" tablets (buclizine 6.25mg, paracetamol 500mg, codeine phosphate 8mg)
"Yellow" tablets (paracetamol 500mg, codeine phosphate 8mg)
|
07.04.02 |
Mirabegron |
M/R tablets
Only recommended if antimuscarinic drugs are contraindicated, clinically ineffective or have unacceptable side effects. |
04.03.04 |
Mirtazapine |
Tablets
Orodispersible tablets |
07.01.01 |
Misoprostol |
Tablets (for oral or vaginal administration)
Unlicensed indication |
07.04.04 |
Mitomycin |
Bladder instillation |
11.99.99.99 |
Mitomycin C |
Subconjunctival injection
Prepared by pharmacy aseptics unit on named-patient basis |
24.03 |
Mitoxantrone IV Infusion |
|
15.01.05 |
Mivacurium Chloride Mivacron® |
|
04.03.02 |
Moclobemide |
|
04.04 |
Modafinil |
Tablets
AMBER for sleepiness associated with narcolepsy
|
12.02.01 |
Mometasone Furoate Nasonex® |
Nasal Spray |
13.04 |
Mometasone Furoate 0.1% Non-proprietary or Elocon® |
Cream
Ointment
Dermatology only |
03.03.02 |
Montelukast Singulair® |
Tablets
Chewable Tablets
Granules
The Scottish Medicines Compendium has advised (June 2007) that montelukast chewable tablet and granules are restricted for use as an alternative treatment option to low-dose inhaled corticosteroids for children 2 to 14 years of age with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids.
The chewable tablets and granules should be initiated by specialists in paediatric asthma care.
|
04.07.02 |
Morphine |
Oral solution:
10mg/5mL
100micrograms/mL ( unlicensed)
Concentrated oral solution:
100mg/5mL
Tablets
M/R 12-hourly oral preparations:
Zomorph® capsules
MST® tablets
M/R 24-hourly oral preparations:
MXL® capsules
Suppositories
Injection
PCA syringe ( unlicensed)
|
01.06.05 |
Moviprep® |
|
05.01.12 |
Moxifloxacin |
Tablets
Intravenous Infusion
Can only be prescribed following discussion with Microbiology or an ID physician |
02.05.02 |
Moxonidine |
Tablets
Specialist initiation only
Moxonidine is considered a last-line management option for resistant hypertension.
|
09.06.07 |
Multivitamin preparations Abidec® |
Oral drops |
09.06.07 |
Multivitamin preparations Dalivit® |
Oral drops
Only use if Abidec is unavailable |
13.10.01.01 |
Mupirocin Bactroban® |
See 12.02.03 |
12.02.03 |
Mupirocin 2% in White Soft Paraffin Bactroban Nasal® |
Nasal ointment
For MRSA eradication only |
09.06.07 |
Mutivitamins |
Capsules |
10.01.03 |
Mycophenolate |
Tablets Capsules
unlicensed indication (rheumatoid arthritis). |
08.02.01 |
Mycophenolate Mofetil |
Capsules
Tablets
Oral suspension
All new patients commenced on mycophenolate mofetil should be commenced on a "branded generic" preparation. |
13.05.03 |
Mycophenolate mofetil |
Tablets
Capsules
Oral suspension
unlicensed indication (severe refractory eczema) |
08.02.01 |
Mycophenolic Acid Myfortic® |
Gastro-resistant tablets
Mycophenolate and mycophenolic acid are not interchangeable. Patients on Myfortic® must remain on Myfortic®.
|
08.02.01 |
Mycophenolic Acid Myfortic® |
Gastro-resistant tablets
Mycophenolate and mycophenolic acid are not interchangeable. Patients on Myfortic® must remain on Myfortic®.
|
11.08.02 |
Mydrane Lidocaine / Phenylephrine / Tropicamide |
3rd line for patients intolerant to Mydriasert or where the individual drops are ineffective |
24.03 |
Mytomycin Ophthalmic |
|
10.01.01 |
Nabumetone |
Tablets
Oral suspension |
02.06.04 |
Naftidrofuryl Oxalate |
Tablets
Naftidrofuryl is an option for the treatment of intermittent claudication in people with peripheral arterial disease for whom vasodilator therapy is considered appropriate after taking into account other treatment options. See NICE TA223: Peripheral Arterial Disease. |
01.06.06 |
Naloxegol Moventig® |
Tablets
Treatment of opioid-induced constipation in adults who have had inadequate response to two laxatives
|
04.10.01 |
Naltrexone |
Tablets |
04.10.03 |
Naltrexone |
Specialist initiation only |
10.01.01 |
Naproxen |
Tablets |
11.03.02 |
Natamycin Natacyn® |
5% eye drops
First line for filamentous fungi
|
06.01.02.03 |
Nateglinide Starlix® |
Tablets |
02.04 |
Nebivolol Nebilet® |
Tablets
Highly cardio-selective. Can be considered in patients with severe COPD or asthma, when benefits of beta-blockade are thought to outweigh the respiratory risks, under specialist supervision with PEFR monitoring in hospital. Can also be tried in patients who develop wheeze with less cardioselective beta-blockers.
Usual to start at 1.25mg and uptitrate. This will involve the use of quarter of a 5mg tablet. |
11.04.02 |
Nedocromil Rapitil® |
Eye drops |
04.07.01 |
Nefopam |
Tablets
Only to be used in those patients with moderate to severe chronic liver disease who require analgesia stronger than paracetamol in whom NSAIDS and moderate strength opiates are contraindicated
|
09.04 |
Neocate Active |
|
09.04.02 |
Neocate Advance |
Dose calculated by dietitian |
09.04 |
Neocate LCP |
Dose dependent on age |
09.04 |
Neocate Spoon |
Dose dependent on age |
05.01.04 |
Neomycin Sulphate |
Tablets |
12.01.01 |
Neomycin Sulphate with corticosteroids Otosporin® |
Ear drops
Not on GMMMG formulary
|
24.02 |
Neonatal TPN Maintenance Extra Protein |
|
24.02 |
Neonatal TPN Start-Up Extra Protein |
|
10.02.01 |
Neostigmine |
Tablets
Injection (see chapter 15) |
15.01.06 |
Neostigmine with Glycopyrronium |
|
11.08.02 |
Nepafenac Nevanac® |
Eye drops (0.1% and 0.3%)
Diabetic patients only |
05.03.01 |
Nevirapine Viramune® |
|
05.05.03 |
Niclosamide |
Tablets
unlicensed |
02.06.03 |
Nicorandil Ikorel® |
Tablets
Indicated for stable angina only in patients whose angina is inadequately controlled by first-line anti-anginal therapies, or who have a contra-indication or intolerance to first-line therapies, such as beta-blockers and/or calcium channel blockers. |
04.10.02 |
Nicotine |
Patch (16 hour) Patch (24 hour)
Chewing gum
S/L tablets ("Microtabs")
Inhalator
Lozenge
Nasal spray
Mouth spray
|
04.10.02 |
Nicotine Nicotinell® |
Patch (24 hour)
Lozenge |
02.06.02 |
Nifedipine |
Modified release capsules
Standard release capsules Raynauds phenomenon. Not recommended for angina prophylaxis or hypertension
Specify the brand when prescribing a modified release nifedipine preparation.
Short-acting formulations of nifedipine are not recommended for angina or long-term management of hypertension; their use may be associated with large variations in blood pressure and reflex tachycardia. (BNF) |
07.01.03 |
Nifedipine |
Capsules
Unlicensed indication |
02.06.02 |
Nimodipine Nimotop® |
Tablets
Intravenous Infusion
For prevention (oral) and treatment (IV) of ischaemic neurological deficits following aneurysmal subarachnoid haemorrhage. |
04.01.01 |
Nitrazepam |
Tablets
Oral suspension |
05.01.13 |
Nitrofurantoin |
Tablets
Capsules
M/R capsules
Oral Suspension
|
15.01.02 |
Nitrous oxide |
|
02.07.02 |
Noradrenaline / Norepinephrine |
Injection (for intravenous infusion; dilute before use). |
06.04.01.02 |
Norethisterone |
Tablets |
07.03.02 |
Norgeston® Levonorgestrel 30mcg |
|
07.03.02 |
Noriday® Norethisterone 350mcg |
|
07.03.01 |
Norimin® Ethinylestradiol 35 mcg / noresthisterone 1mg |
Standard strength preparation |
14.05.01 |
Normal immunoglobulin for Intravenous use Vigam® |
Established patients only |
14.05.01 |
Normal immunoglobulin for Intravenous use Octagam® |
|
14.05.01 |
Normal immunoglobulin for subcutaneous or intramuscular use Subgam® |
Only for prophylaxis of tetanus-prone wounds when IM tetanus immunoglobulin unavailable
See Public Health England (PHE) Guidance for full details |
04.03.01 |
Nortriptyline |
Tablets |
06.01.05 |
Nortriptyline |
Tablets
unlicensed
Useful if the patient gains benefit from amitriptyline but experiences side/adverse effects |
06.01.01.02 |
NovoMix® 30 Biphasic Insulin Aspart |
3ml cartridge (via Novopen® 4 device)
3ml prefilled disposable pen (Flexpen®)
|
06.01.01.01 |
NovoRapid® Insulin Aspart |
3ml cartridge (via Novopen® devices)
3ml prefilled disposable pen (Flexpen®)
|
09.04 |
Nutriprem 2 |
Dose dependent on age |
09.04 |
Nutriprem Hydrolysed |
Dose dependent on age |
07.03.01 |
NuvaRing® Ethinylestradiol / etonogestrel |
Low strength vaginal ring |
12.03.02 |
Nystatin Nystan® |
Oral suspension |
13.10.02 |
Nystatin Cream |
Cream |
13.10.02 |
Nystatin with Chlorhexidine cream Nystaform® |
Cream |
08.02.03 |
Obinutuzumab Gazyvaro® |
Concentrate for intravenous infusion
Specialist use only; for previously untreated chronic lymphocytic leukaemia (CLL) in patients with comorbidities making them unsuitable for full-dose fludarabine-based therapy |
24.03 |
Obinutuzumab IV Infusion |
|
08.03.04.03 |
Octreotide |
Solution for injection (various forms) Depot injection (Sandostatin LAR®) |
07.02.01 |
Oestrogens, Topical Gynest® |
0.01% intravaginal cream |
07.02.01 |
Oestrogens, Topical Vagifem® |
Vaginal tablets |
08.02.03 |
Ofatumumab Arzerra® |
Concentrate for intravenous infusion
Specialist use only; CDF criteria must be met & funding approval received. |
24.03 |
Ofatumumab IV Infusion |
|
05.01.12 |
Ofloxacin |
Tablets
(Intravenous infusion is non-formulary) |
11.03.01 |
Ofloxacin Eye drops |
Eye drops
|
13.02.01 |
Oilatum® |
Cream |
13.02.01.01 |
Oilatum® Bath Additive |
|
13.02.01.01 |
Oilatum® Plus emollient bath additive |
|
13.02.01.01 |
Oilatum®Plus Bath Additive |
|
01.07.03 |
Oily Phenol Injection BP |
Specialist administration only |
04.02.01 |
Olanzapine |
Tablets
Orodispersible tablets |
12.01.03 |
Olive Oil Ear Drops |
Ear drops
|
11.04.02 |
Olopatadine Opatanol® |
Eye drops |
01.05.01 |
Olsalazine |
Capsules
Tablets
Specialist initiation only |
03.04.02 |
Omalizumab Xolair® |
Subcutaneous injection |
05.03.03.02 |
Ombitasvir/Paritaprevir/Ritonavir Viekirax® 12.5mg/75mg/50mg |
Tablets
Requires MDT discussion with ID team |
02.12 |
Omega-3-Acid Ethyl Esters |
Capsules
Should only be used for the treatment of hypertriglyceridaemia under the care of a lipid management specialist.
Omega-3-Acid Ethyl Esters are NOT recommended for the secondary prevention of Myocardial Infarction. See GMMMG IPNTS recommendation. |
01.03.05 |
Omeprazole |
Capsules
Injection Only for use in ventilated patients to prevent ventilator associated pneumonia and in patients who have received an endoscopic intervention for upper gastro-intestinal bleeding.
Swallowing difficulties: Patients can open the capsule and swallow the contents with half a glass of water or mix the contents in fruit juice or non-carbonated water. Patients should be advised that the dispersion should be taken within 30 minute and always be stirred just before drinking and rinsed down with half a glass of water. |
04.06 |
Ondansetron |
Tablets Injection Oral lyophilisates (’melts’) Suppositories
For exceptional use in non-oncology patients with chronic emesis following consultant recommendation and where all other options have failed |
04.06 |
Ondansetron |
Tablets
Oral lyophilisates ('melts')
Injection
Suppositories |
04.09.01 |
Opicapone Ongentys® |
Capsules |
06.01.06 |
Oral glucose tolerance test. |
|
09.02.01.02 |
Oral Rehydration Salts e.g. Dioralyte® |
Oral powder |
04.05.01 |
Orlistat |
|
04.09.02 |
Orphenadrine |
Tablets
Oral liquid |
05.03.04 |
Oseltamivir Tamiflu® |
Capsules
Oral Suspension |
09.04.02 |
Osmolite |
500ml 1000ml 1500ml
|
09.04.02 |
Osmolite 1.5kcal |
500ml 1000ml 1500ml
|
09.04.02 |
Osmolite HP |
|
09.04.02 |
Osmolite PLUS |
500ml 1000ml 1500ml
|
07.03.01 |
Ovysmen® Ethinylestradiol 35 mcg / noresthisterone 500mcg |
Standard strength preparation |
04.01.02 |
Oxazepam |
|
04.08.01 |
Oxcarbazepine |
Tablets |
11.07 |
Oxybuprocaine Hydrochloride Minims® |
Single-use eye drops |
07.04.02 |
Oxybutynin |
Tablets
M/R tablets
Patches ( only when the oral route is not tolerated) |
04.07.02 |
Oxycodone |
Immediate-release preparations (OxyNorm®):
Oral solution 5mg/5mL
Concentration oral solution 10mg/mL
Capsules
Injection
M/R preparations (OxyContin®):
Tablets |
05.01.03 |
Oxytetracycline |
Tablets |
13.06.02 |
Oxytetracycline |
Tablets
First choice for acne and rosacea |
07.01.01 |
Oxytocin Syntocinon® |
Injection |
09.04 |
Paediasure 200ml Bottle |
|
09.04.02 |
Paediasure 500ml Bag |
Dose calculated by dietitian |
09.04 |
Paediasure Fibre 200ml Bottle |
Dose dependent on age |
09.04.02 |
Paediasure Fibre 500ml Bag |
Dose calculated by dietitian |
09.04 |
Paediasure Peptide 200ml Bottle |
|
09.04.02 |
Paediasure Peptide 500ml Bag |
Dose calculated by dietitian |
09.04 |
Paediasure Plus 200ml Bottle |
Dose dependent on age |
09.04.02 |
Paediasure Plus 500ml Bag |
Dose calculated by dietitian |
09.04 |
Paediasure Plus Fibre 200ml Bottle |
|
09.04.02 |
Paediasure Plus Fibre 500ml Bag |
Dose calculated by dietitian |
09.04 |
Paediasure Plus Juice 200ml Bottle |
|
05.03.05 |
Palivizumab Synagis® |
Injection |
04.06 |
Palonosetron Aloxi® |
Approved for emesis following breast cancer chemotherapy (2nd line after ondansetron) |
05.01.09 |
P-aminosalicylic acid Paser® |
Sachets
unlicensed
Can only be prescribed following discussion with an ID physician |
01.09.04 |
Pancreatin Creon® 10000 |
|
01.09.04 |
Pancreatin Creon® Micro |
|
01.09.04 |
Pancreatin Creon® 25000 |
|
01.09.04 |
Pancreatin Pancrex V® |
For administration via enteral feeding tubes |
01.09.04 |
Pancreatin Creon® 40000 |
|
15.01.05 |
Pancuronium Bromide |
|
04.07.01 |
Paracetamol |
Tablets
Soluble tablets
Oral suspension
Suppositories
IV infusion
|
04.07.01 |
Paracetamol and codeine Co-codamol® 8/500 |
Tablets
Effervescent tablets |
04.07.01 |
Paracetamol and codeine Co-codamol® 30/500 |
Tablets
Effervescent tablets |
04.07.01 |
Paracetamol and dihydrocodeine Co-dydramol® 10/500 |
Tablets |
04.08.02 |
Paraldehyde Enema |
Paediatric use only |
15.01.04.02 |
Parecoxib Dynastat® |
|
09.03 |
Parenteral Nutrition (TPN) |
See Chapter 24 for full list of TPN bags available.
Please see Appendix 3 of attached link for details on out-of-hours TPN use |
04.03.03 |
Paroxetine |
Tablets
Oral suspension |
09.01.06 |
Pegfilgrastim Neulasta® |
Injection |
05.03.03.01 |
Peginterferon Alfa |
Injection |
05.03.03.02 |
Peginterferon Alfa |
Injection |
08.02.04 |
Peginterferon Alfa Pegasys® |
First line choice for chronic hepatitis C |
08.02.04 |
Peginterferon Alfa ViraferonPeg® |
For chronic hepatitis C patients >120kg in weight. |
09.08.01 |
Penicillamine |
Tablets |
10.01.03 |
Penicillamine |
Tablets |
11.03.01 |
Penicillin G |
Eye drops unlicensed special
|
05.04.05 |
Pentamidine Isetionate |
Injection |
05.04.08 |
Pentamidine Isetionate |
Injection |
24.01 |
Pentamidine IV Infusion |
|
24.03 |
Pentostatin IV Infusion |
|
02.06.04 |
Pentoxifylline Trental® |
Tablets
For alcoholic liver disease.
Not recommended for the treatment of intermittent claudication in patients with peripheral arterial disease, but patients currently taking pentoxifylline should have the option to continue until they and their clinican considers it appropriate to stop. (NICE TA223:Peripheral Arterial Disease) |
01.02 |
Peppermint Oil e/c capsules |
|
09.04 |
Pepti Junior Cow and Gate |
Dose dependent on age |
04.08.01 |
Perampanel Fycompa® |
Tablets |
04.09.01 |
Pergolide |
Tablets |
04.02.01 |
Pericyazine |
Tablets |
02.05.05.01 |
Perindopril erbumine |
Tablets
Prescribers are reminded that perindopril should be prescribed generically. Perindopril arginine (Coversyl Arginate®) is not dose equivalent and is not included in the formulary.
|
13.10.04 |
Permethrin 1% Lyclear® Creme Rinse |
INSUFFICIENT CONTACT TIME, THEREFORE NOT RECOMMENDED |
13.10.04 |
Permethrin 5% Lyclear® Dermal Cream |
Cream |
04.02.01 |
Perphenazine |
Tablets |
04.07.02 |
Pethidine |
Tablets
Injection |
04.03.02 |
Phenelzine |
|
02.08.02 |
Phenindione |
Tablets |
02.08.02 |
Phenindione |
Tablets |
04.08.01 |
Phenobarbital |
Tablets
Elixir
Injection
Ensure patients are maintained on a specific manufacturer's product / brand |
04.08.02 |
Phenobarbital Injection |
|
02.05.04 |
Phenoxybenzamine Hydrochloride |
Capsules
(Injection is non-formulary) |
05.01.01.01 |
Phenoxymethylpenicillin |
Tablets
Oral Solution |
02.05.04 |
Phentolamine Rogitine® |
Injection
For hypertensive episodes due to phaeochromocytoma, e.g. during surgery (BNF).
|
02.07.02 |
Phenylephrine |
Injection |
11.05 |
Phenylephrine Hydrochloride Minims® Phenylephrine Hydrochloride |
2.5% and 10% Single-use eye drops |
04.08.01 |
Phenytoin |
Capsules
Suspension 30mg/5mL
Chewable tablets
Injection
Ensure patients are maintained on a specific manufacturer's product / brand |
04.08.02 |
Phenytoin Injection |
See loading doses policy |
03.09.01 |
Pholcodine |
Oral solution |
09.05.02.01 |
Phosphate effervescent tablets Phosphate-Sandoz® |
|
09.05.02.01 |
Phosphate Polyfusor® |
500ml Polyfusor |
01.06.05 |
Phosphates (oral) Fleet Phospho-soda® |
|
01.06.04 |
Phosphates Enema |
|
09.06.06 |
Phytomenadione |
1ml amps (Konakion®MM)
0.2ml amps (Konakion®MM Paediatric) - may be given orally
|
11.06 |
Pilocarpine |
1%, 2%, 4% eye drops
2% single-use eye drops (Minims®)
|
13.05.03 |
Pimecrolimus 1% Cream Elidel® |
Cream
Consultant Dermatologist only, in line with NICE Guidance
|
04.02.01 |
Pimozide |
Tablets |
06.01.02.03 |
Pioglitazone Actos® |
Tablets |
24.01 |
Piperacillin / Tazobactam IV Infusion |
4.5gram in 100mL sodium chloride 0.9% |
05.01.01.04 |
Piperacillin and Tazobactam |
Injection |
04.02.02 |
Pipotiazine Palmitate Piportil® |
|
10.03.02 |
Piroxicam gel |
Gel |
05.01.01.05 |
Pivmecillinam Hydrochloride Selexid® |
Tablets |
24.03 |
Pixantrone IV Infusion |
|
04.07.04.02 |
Pizotifen |
Tablets |
09.02.02.01 |
Plasma-Lyte 148® solution for infusion |
Not for use in pre-term neonates
|
09.02.02.01 |
Plasma-Lyte 148® solution for infusion |
Not for use in pre-term neonates
|
14.04 |
Pneumococcal vaccine Prevenar 13® |
|
14.04 |
Pneumococcal vaccine |
Previously known as Pneumovax II® |
13.07 |
Podophyllotoxin Condyline®or Warticon® |
|
09.04 |
Polycal |
Dose calculated by dietitian |
06.01.06 |
Polycal® |
|
13.10.01.01 |
Polyfax® Ointment |
Ointment |
14.04 |
Polysaccharide vaccine for injection Typhim Vi® |
|
09.02.01.01 |
Polystyrene Sulphonate Resins Calcium Resonium® |
Powder |
13.09 |
Polytar AF® |
Shampoo |
13.09 |
Polytar® |
Liquid |
11.08.01 |
Polyvinyl Alcohol Liquifilm Tears or Sno Tears® |
Eye drops
Brand with lowest aquisition cost will be supplied. |
08.02.04 |
Pomalidomide |
Capsules |
03.05.02 |
Poractant Alfa Curosurf® |
Suspension
Specialist neonatal use only |
05.02.01 |
Posaconazole Noxafil® |
Suspension
Tablets
Specialist (haematology) or ID consultant initiation only. See links
For AML inpatients only. Not to be supplied on discharge |
11.99.99.99 |
Potassium Ascorbate |
Eye drops
unlicensed |
09.02.01.01 |
Potassium Chloride Kay-Cee-L® |
Syrup |
09.02.01.01 |
Potassium Chloride Sando-K® |
Effervescent tablets |
09.02.02.01 |
Potassium Chloride 0.15% and Glucose 10% Intravenous Infusion |
500ml bag (contains 10mmol of potassium)
Unlicensed special - manufactured to order and may not always be available |
09.02.02.01 |
Potassium Chloride 0.15% and Glucose 5% Intravenous Infusion |
500ml bag (contains 10mmol of potassium) |
09.02.02.01 |
Potassium Chloride 0.15% and Sodium Chloride 0.9% Intravenous Infusion |
500ml bag (contains 10mmol of potassium) |
09.02.02.01 |
Potassium Chloride 0.15%, Sodium Chloride 0.18% and Glucose 4% Intravenous Infusion |
500ml bag (contains 10mmol of potassium) |
09.02.02.01 |
Potassium Chloride 0.15%, Sodium Chloride 0.45% and Glucose 5% Intravenous Infusion |
500ml bag (contains 10mmol of potassium) |
09.02.02.01 |
Potassium Chloride 0.3% and Glucose 10% Intravenous Infusion |
500ml bag (contains 20mmol of potassium)
Unlicensed special - manufactured to order and may not always be available |
09.02.02.01 |
Potassium Chloride 0.3% and Glucose 5% Intravenous Infusion |
500ml bag (contains 20mmol of potassium) |
09.02.02.01 |
Potassium Chloride 0.3% and Sodium Chloride 0.9% Intravenous Infusion |
500ml bag (contains 20mmol of potassium) |
09.02.02.01 |
Potassium Chloride 0.3%, Sodium Chloride 0.18% and Glucose 4% Intravenous Infusion |
500ml bag (contains 20mmol of potassium) |
09.02.02.01 |
Potassium Chloride 0.3%, Sodium Chloride 0.45% and Glucose 10% Intravenous Infusion |
500ml bag (contains 20mmol of potassium)
|
09.02.02.01 |
Potassium Chloride 0.3%, Sodium Chloride 0.45% and Glucose 5% Intravenous Infusion |
500ml bag (contains 20mmol of potassium)
Unlicensed special - manufactured to order and may not always be available |
09.02.02.01 |
Potassium Chloride 0.3%, Sodium Chloride 0.9% and Glucose 5% Intravenous Infusion |
500ml bag (contains 20mmol of potassium) |
09.02.02.01 |
Potassium Chloride 0.6% and Glucose 5% |
500ml bag (contains 40mmol of potassium)
Unlicensed special - manufactured to order and may not always be available
500ml bags containing 40mmol of potassium may be kept as stock in critical
care areas. They will be supplied from the Pharmacy department to other wards
on a named patient basis only. |
09.02.02.01 |
Potassium Chloride 0.6% and Sodium Chloride 0.9% |
500ml bag (contains 40mmol of potassium)
Unlicensed special - manufactured to order and may not always be available
500ml bags containing 40mmol of potassium may be kept as stock in critical
care areas. They will be supplied from the Pharmacy department to other wards
on a named patient basis only. |
09.02.02.01 |
Potassium Chloride 15% Concentrate BP |
10ml amps (Contains 20mmol potassium)
Only the designated areas given in Appendix 1 of the Intravenous Potassium Policy have been authorised to stock and administer strong potassium chloride solutions as indicated. Potassium chloride concentrated solutions must never be transferred between clinical areas
Must be stored in a Controlled Drugs cupboard.
Must NEVER be administered undiluted
(NPSA 'Never Event) |
09.02.02.01 |
Potassium Chloride 3% in Sodium Chloride 0.9% |
100ml bag (contains 40mmol potassium)
Only the designated areas given in Appendix 1 of the Intravenous Potassium Policy have been authorised to stock and administer strong potassium chloride solutions as indicated. Potassium chloride concentrated solutions must never be transferred between clinical areas
Order as a Controlled Drug.
Potassium chloride infusion 40mmol in 100ml sodium chloride 0.9% must be
stored in a locked cupboard and kept separate from other infusion bags. |
07.04.03 |
Potassium Citrate Mixture BP |
Oral solution |
13.11.06 |
Potassium Permanganate Permitabs® |
Solution tablets |
13.11.04 |
Povidone-Iodine Betadine® or Videne® |
|
04.09.01 |
Pramipexole |
Tablets
M/R tablets |
02.09 |
Prasugrel Efient® |
Tablets
See information above, and GMMMG algorithms below. |
02.12 |
Pravastatin |
Tablets |
05.05.03 |
PRAZIQUANTEL Tablets 500 mg |
Tablets
unlicensed
|
05.05.05 |
PRAZIQUANTEL Tablets 500 mg |
Tablets
unlicensed
|
01.05.02 |
Prednisolone |
Tablets
Soluble tablets
Rectal foam
Retention enema
Suppositories
Enema and rectal foam = Green2
|
06.03.02 |
Prednisolone |
Tablets (NOT enteric coated)
Soluble tablets - paediatrics only
|
11.04.01 |
Prednisolone |
Eye drops (0.5% and 1%)
Single use eye drops 0.5% (Minims®)
|
04.07.03 |
Pregabalin |
Capsules
A trial of pregabalin may be considered in patients who cannot tolerate gabapentin, or who have not responded fully despite an adequate trial. |
04.08.01 |
Pregabalin |
Capsules
FOR EPILEPSY. See section 4.7.3 for use in neuropathic pain. |
06.01.05 |
Pregabalin |
Capsules
A trial of pregabalin may be considered in patients who cannot tolerate gabapentin, or who have not responded fully despite an adequate trial. |
06.04.01.01 |
Premarin® |
Tablets
Conjugated oestrogen 300micrograms
Conjugated oestrogen 625micrograms
Conjugated oestrogen 1.25mg
|
06.04.01.01 |
Premique® |
Tablets
Conjugated oestrogen 625micrograms + medroxyprogesterone acetate 5mg
|
06.04.01.01 |
Premique® low dose |
Tablets
Conjugated oestrogen 300micrograms + medroxyprogesterone acetate 1.5mg
|
06.04.01.01 |
Prempak-C® |
Tablets
Conjugated oestrogens 625micrograms + norgestrel 150micrograms
Conjugated oestrogens 1.25mg + norgestrel 150micrograms
|
05.04.01 |
Primaquine |
Tablets |
05.04.08 |
Primaquine |
Tablets |
04.08.01 |
Primidone |
Tablets
Ensure patients are maintained on a specific manufacturer's product / brand |
04.09.03 |
Primidone |
Tablets |
10.01.04 |
Probenecid |
Tablets
unlicensed
|
09.04 |
Procal |
Dose calculated by dietitian |
04.06 |
Prochlorperazine |
Tablets Buccal tablets (Buccastem®) Syrup Injection |
04.06 |
Prochlorperazine |
Tablets
Buccal tablets (Buccastem®)
Syrup
Injection |
04.06 |
Prochlorperazine |
Tablets Buccal tablets (Buccastem®) Syrup Injection |
04.09.02 |
Procyclidine |
Tablets
Syrup
Injection |
13.10.05 |
Proflavine Cream, BPC |
Cream |
06.04.01.02 |
Progesterone Cyclogest® |
Pessaries/suppositories
"Red" when used for infertility |
06.04.01.02 |
Progesterone Gestone® |
Injection |
05.04.01 |
Proguanil Hydrochloride |
Tablets |
05.04.01 |
Proguanil Hydrochloride with Atovaquone Malarone® |
Tablets |
04.02.01 |
Promazine Hydrochloride |
Tablets
Oral solution
Only licensed for agitation |
03.04.01 |
Promethazine |
Tablets
Elixir
Injection
|
04.01.01 |
Promethazine Hydrochloride |
Tablets
Elixir
Injection |
04.06 |
Promethazine Hydrochloride |
Tablets
Elixir
Injection |
04.06 |
Promethazine Hydrochloride |
Tablets Elixir Injection |
02.03.02 |
Propafenone |
|
11.03.01 |
Propamidine Isetionate Brolene® |
Eye drops
Used with chlorhexidine for treatment of acanthamoeaba keratitis only |
15.01.01 |
Propofol |
|
02.04 |
Propranolol |
Tablets
Modified Release Capsules
Liquid
|
04.07.04.02 |
Propranolol |
Tablets
M/R capsules
Oral solution |
04.09.03 |
Propranolol |
Tablets
M/R capsules
Oral solution |
06.02.02 |
Propylthiouracil |
Tablets
Prescribing to remain with specialist care until stable. |
02.08.03 |
Protamine Sulphate |
Injection |
05.01.09 |
Prothionamide |
Tablets
unlicensed
Can only be prescribed following discussion with an ID physician |
11.07 |
Proxymetacaine Hydrochloride Minims® |
Single-use eye drops |
01.06.07 |
Prucalopride Resolor® |
Tablets
Consultant only
Initial 2-weeks supply from hospital
|
03.10 |
Pseudoephedrine Hydrochloride |
Tablets
Elixir |
13.05.02 |
Psoriderm® Coal tar 6% |
Cream |
05.01.09 |
Pyrazinamide |
Tablets |
10.02.01 |
Pyridostigmine Bromide |
Tablets |
05.01.09 |
Pyridoxine |
Tablets
|
09.06.02 |
Pyridoxine Hydrochloride |
Tablets
Injection
Oral Solution unlicensed |
05.04.01 |
Pyrimethamine |
Tablets |
05.04.07 |
Pyrimethamine |
Tablets |
04.02.01 |
Quetiapine |
Tablets
M/R tablets
|
05.04.01 |
Quinine |
Tablets
Injection |
10.02.02 |
Quinine Sulphate |
Tablets |
13.02.01 |
QV® |
Skin lotion
Cream
Intensive ointment
Only on advice of tissue viability |
13.02.01.01 |
QV® |
Bath oil
Gentle wash
Only on advice of tissue viability |
14.05.02 |
Rabies Immunoglobulin |
Medical team to contact Clinical Virology at Central Manchester Foundation Trust (0161 276 8853) |
14.04 |
Rabies vaccine |
Pre-exposure vaccination: NMGH Travel Clinic only |
06.04.01.01 |
Raloxifene Hydrochloride Evista® |
Tablets |
05.03.01 |
Raltegravir Isentress ® |
|
02.05.05.01 |
Ramipril |
Capsules |
11.08.02 |
Ranibizumab Lucentis® |
Intravitreal injection
Ophthalmic consultant only
Use as per GMMMG Macular Drugs Pathway |
01.03.01 |
Ranitidine |
Tablets
Effervesent tablets
Syrup
Injection |
02.06.03 |
Ranolazine Ranexa® |
Tablets
Restricted to cardiac services (PAHT)
For stable angina where patients are unsuitable for physical therapy or first and second line agents (PAHT). |
10.01.04 |
Rasburicase Fastertec® |
Intravenous infusion |
04.03.04 |
Reboxetine |
|
15.01.04.03 |
Remifentanil Ultiva® |
|
06.01.02.03 |
Repaglinide Prandin® |
Tablets |
03.04.02 |
Reslizumab Cinqaero® |
IV infusion |
04.08.01 |
Retigabine |
Tablets
|
05.03.03.02 |
Ribavirin Copegus® |
Tablets |
05.01.09 |
Rifabutin Mycobutin® |
Capsules
Can only be prescribed following discussion with an ID Physician |
05.01.09 |
Rifampicin |
Capsules
Tablets
Syrup
Intravenous Infusion
No restrictions on use for non-tuberculosis indications. |
05.01.09 |
Rifampicin and Isoniazid Rifinah® |
Tablets
For continuation (maintenance) phase of treatment |
05.01.09 |
Rifampicin and Isoniazid and Pyrazinamide Rifater® |
Tablets
2nd line option with a 4th agent |
05.01.09 |
Rifampicin, isoniazid, pyrazinamide and ethambutol Voractiv® |
Tablets |
05.01.07 |
Rifaximin |
Gastroenterologists only
Initial 2 weeks supply provided by secondary care. |
05.03.01 |
Rilpivirine hydrochloride Edurant® |
|
04.09.03 |
Riluzole |
Tablets |
11.04.01 |
Rimexolone Vexol® |
Eye drops |
06.06.02 |
Risedronate |
35mg tablets (once weekly preparation) |
04.02.01 |
Risperidone |
Tablets
Orodispersible tablets
Liquid |
04.02.02 |
Risperidone Risperdal Consta® |
|
05.03.01 |
Ritonavir Norvir® |
|
08.02.03 |
Rituximab MabThera® |
Concentrate for intravenous infusion
Specialist use only |
10.01.03 |
Rituximab |
Intravenous Infusion |
24.03 |
Rituximab IV Infusion |
|
24.03 |
Rituximab SC Injection |
|
02.08.02 |
Rivaroxaban Xarelto® |
Tablets
|
02.08.02 |
Rivaroxaban Xarelto® |
Tablets
|
02.08.02 |
Rivaroxaban Xarelto® |
Tablets
|
04.11 |
Rivastigmine |
Capsules
Oral solution
Patch
Commissioning arrangements may vary and in some localities this is Green2 - check with relevant CCG |
15.01.05 |
Rocuronium Bromide Esmeron® |
|
03.03.03 |
Roflumilast Daxas® |
Tablets |
09.01.04 |
Romiplostim Nplate® |
Injection
PbR excluded - commissioned by CCG
Prescribers need to ensure manufacturer makes romiplostim available with the discount agreed as part of the patient access scheme. |
04.09.01 |
Ropinirole |
Tablets
M/R tablets |
02.12 |
Rosuvastatin |
Tablets
Approved for use in PAHNT for patients who have not achieved target levels with other statins. |
14.04 |
Rotavirus vaccine Rotarix® |
|
04.09.01 |
Rotigotine Patch |
Only for patients unable to tolerate or comply with oral medication. |
04.08.01 |
Rufinamide |
|
04.09.01 |
Safinamide Xadago |
Tablet |
03.01.01.01 |
Salbutamol |
Dry powder inhaler (DPI)(Easyhaler®)
Breath-actuated inhaler (Airomir® Autohaler, Salamol Easi-breathe®)
Dry powder inhaler(Ventolin®Accuhaler) |
03.01.01.01 |
Salbutamol |
Inhalers (see separate entries)
Nebuliser solution
Tablets
Oral solution
Injection
Solution for infusion
The use of short-acting adrenoreceptor agonists for tocolyis in premature labour has been restricted to 48 hours maximum parenteral use under specialist supervision, after a European safety review (MHRA 2013 - see Drug Safety Update) |
03.01.01.01 |
Salbutamol |
Brands include Ventolin Evohaler®, Airomir® inhaler.
|
07.01.03 |
Salbutamol |
Injection |
13.07 |
Salicylic Acid 16.7% with Lactic Acid 16.7% Salactol®or Duofilm® |
Paint |
01.01 |
Salicylic Acid Ointment |
Ointment |
13.10.02 |
Salicylic Acid Ointment |
Ointment |
03.01.01.01 |
Salmeterol |
Metered dose inhaler 25 micrograms/dose (Serevent Evohaler®)
Dry powder inhaler (Serevent Accuhaler®)
|
09.06.07 |
Sanatogen A-Z |
Tablets |
10.01.03 |
Sarilumab Kavzara® |
Pre-filled syringe or pen |
24.03 |
Savene IV Infusion |
|
06.01.02.03 |
Saxagliptin Onglyza® |
Tablets
For established patients only. Alogliptin is first line.
|
01.07.02 |
Scheriproct® |
Ointment
Suppositories |
13.05.02 |
Sebco® |
Scalp Ointment |
10.01.03 |
Secukinumab Cosentyx® |
Pre-filled syringe
|
13.05.03 |
Secukinumab Cosentyx® |
|
04.09.01 |
Selegiline Hydrochloride |
Tablets |
13.09 |
Selenium Sulphide 2.5% Shampoo Selsun® |
Shampoo |
06.01.02.03 |
Semaglutide Ozempic® |
Disposable pen
Once-weekly preparation
|
06.01.01.02 |
Semglee® Insulin Glargine |
3mL pre-filled disposible pen |
01.06.02 |
Senna |
Tablets
Syrup |
04.03.03 |
Sertraline |
Tablets |
09.05.02.02 |
Sevelamer Hydrochloride Renagel® |
Tablets |
15.01.02 |
Sevoflurane |
|
02.05.01 |
Sildenafil |
Tablets (Revatio®)
Suspension (paediatric use) unlicensed
Formulary for treatment of pulmonary arterial hypertension.
For erectile dysfunction, see chapter 7.4.5.
|
07.04.05 |
Sildenafil |
Tablets |
13.07 |
Silver Nitrate 95% with Potassium Nitrate 5% AVOCA® |
Caustic Applicator (stick) |
13.10.01.01 |
Silver Sulfadiazine 1% Cream Flamazine® |
Cream |
05.03.03.02 |
Simeprevir Olysio® |
Requires MDT discussion with ID team
For resistant cases only |
01.01.01 |
Simeticone infacol® |
|
09.04 |
Similac alimentum |
Dose dependent on age |
09.04 |
Similac High Energy |
Dose dependent on age |
03.09.02 |
Simple Linctus, BP |
Oral solution |
03.09.02 |
Simple Linctus, Paediatric BP |
Oral solution |
02.12 |
Simvastatin |
Tablets
|
13.02.02 |
Siopel® |
Cream |
06.01.02.03 |
Sitagliptin Januvia® |
Tablets
For established patients only. Alogliptin is first line.
|
24.02 |
SMOFlipid 20% with vitamins |
50mL syringe |
10.01.03 |
Sodium Aurothomalate Myocrisin® |
Injection |
09.08.01 |
Sodium Benzoate |
|
07.04.03 |
Sodium Bicarbonate |
Capsules
Tablets |
09.02.01.03 |
Sodium Bicarbonate |
Capsules
Tablets
|
09.02.02.01 |
Sodium Bicarbonate Polyfusor® |
1.26%
1.4%
4.2%
8.4% |
09.02.02.01 |
Sodium Bicarbonate |
4.2% 5ml amps unlicensed
4.2% 10ml amps unlicensed
8.4% 10ml amps |
09.02.02.01 |
Sodium Bicarbonate Minijet® |
4.2% 10ml Minijet
8.4% 10ml Minijet
8.4% 50ml Minijet
|
12.01.03 |
Sodium Bicarbonate |
Ear drops |
09.02.01.02 |
Sodium Chloride Slow Sodium® |
Modified release tablets |
09.02.02.01 |
Sodium Chloride 0.18% and Glucose 10% Intravenous Infusion |
500ml bag |
09.02.02.01 |
Sodium Chloride 0.18% and Glucose 4% Intravenous Infusion |
500ml bag
1L bag |
09.02.02.01 |
Sodium Chloride 0.45% and Glucose 10% Intravenous Infusion |
500ml bag |
09.02.02.01 |
Sodium Chloride 0.45% and Glucose 5% Intravenous Infusion |
500ml bag
|
09.02.02.01 |
Sodium Chloride 0.45% Infusion |
500ml bag |
03.01.05 |
Sodium Chloride 0.9% |
Nebuliser solution |
13.11.01 |
Sodium Chloride 0.9% |
Solution |
09.02.02.01 |
Sodium Chloride 0.9% and Glucose 5% Intravenous Infusion |
500ml bag
1L bag |
09.02.02.01 |
Sodium Chloride 0.9% Infusion |
50ml bag
100ml bag
250ml bag
500ml bag
500ml polyfusor
1L bag |
09.02.02.01 |
Sodium Chloride 0.9% Injection |
2ml amps
5ml amps
10ml amps
20ml amps
|
12.02.02 |
Sodium Chloride 0.9% Nose Drops |
Nose drops |
11.08.01 |
Sodium Chloride 0.9% Solutions |
Single-use eye drops
|
11.99.99.99 |
Sodium Chloride 5% |
Preservative-free Eye drops
unlicensed |
12.03.04 |
Sodium Chloride Mouthwash, Compound BP |
Mouthwash |
09.02.02.01 |
Sodium Chloride Polyfusor (500ml) |
0.18%
0.9%
1.8%
2.7%
5% |
01.06.04 |
Sodium Citrate Micro-enema® |
|
06.06.02 |
Sodium Clodronate |
Tablets
Specialist Initiation Only |
11.04.02 |
Sodium Cromoglicate |
Eye drops |
09.01.01.01 |
Sodium Feredetate Sytron® |
27.5mg iron per 5ml |
05.01.07 |
Sodium fusidate |
Tablets
Oral Suspension
Injection ID/microbiologist recommendation only |
11.08.01 |
Sodium Hyaluronate |
Eye drops (brand with lowest aquisition cost will be supplied) 1.2% syringe (BVI OVD®) 2.5% syringe (BVI Multivisc®)
|
02.05.01 |
Sodium Nitroprusside |
Intravenous infusion
unlicensed |
09.08.01 |
Sodium Phenybutyrate Ammonaps® |
|
01.06.02 |
Sodium Picosulfate |
Elixir |
01.06.05 |
Sodium Picosulfate with Magnesium Citrate Citrafleet® or Picolax® |
|
05.04.05 |
Sodium Stibogluconate Pentostam® |
Injection |
02.13 |
Sodium Tetradecyl Sulphate Fibro-Vein® |
Injection |
04.08.01 |
Sodium Valproate |
Tablets (e/c)
Crushable tablets
M/R tablets
Syrup
Injection
|
05.03.03.02 |
Sofosbuvir Sovaldi® |
Tablets
Requires MDT discussion with ID team |
05.03.03.02 |
Sofosbuvir / Velpatasvir Epclusa® |
Tablets
Requires MDT discussion with ID team |
05.03.03.02 |
Sofosbuvir / Velpatasvir / Voxilaprevir Vosevi® |
Tablets
Requires MDT discussion with ID team |
07.04.02 |
Solifenacin |
Tablets |
02.04 |
Sotalol |
Tablets
Specialist initiation
Sotalol is an option for managing life-threatening arrhythmias.
|
02.02.03 |
Spironolactone |
Tablets
Suspension
Spironolactone is significantly cheaper than eplerenone but there is no data available to compare cost-effectivess in particular groups of patients. |
13.02.02 |
Sprilon® |
Spray |
05.03.01 |
Stavudine Zerit® |
Capsules
Oral Solution
Only for patients already established on this treatment |
01.06.01 |
Sterculia Normacol® |
Granules |
02.10.02 |
Streptokinase |
Injection |
05.01.09 |
Streptomycin Sulphate |
Intramuscular Injection
Can only be prescribed following discussion with an ID physician. |
06.06.02 |
Strontium Ranelate Protelos® |
Granules
Specialist Initiation Only |
01.03.03 |
Sucralfate Antepsin® |
Tablets
Suspension
Following reports of bezoar formation associated with sucralfate, caution is advised in seriously ill patients, especially those receiving concomitant enteral feeds or those with predisposing conditions such as delayed gastric emptying
|
13.02.02 |
Sudocrem® |
Cream |
15.01.06 |
Sugammadex Bridion® |
|
05.01.08 |
Sulfadiazine |
Tablets
Can only be prescribed following discussion with ID Physician. See BHIVA Guidelines
|
05.04.07 |
Sulfadiazine |
Tablets
Can only be prescribed following discussion with an ID physician |
01.05.01 |
Sulfasalazine |
Tablets
Suspension |
10.01.03 |
Sulfasalazine |
Enteric coated tablets |
10.01.04 |
Sulfinpyrazone |
Tablets
|
04.02.01 |
Sulpiride |
Tablets
Oral solution |
04.07.04.01 |
Sumatriptan |
Tablets
Injection |
04.07.04.03 |
Sumatriptan |
Injection |
13.08.01 |
Sunsense® Ultra SPF 50+ |
Lotion
Preparations with an SPF less than 30 should not be prescribed. |
15.01.05 |
Suxamethonium Chloride |
|
13.09 |
T/Gel® Therapeutic Shampoo Coal tar extract 2% |
Shampoo |
13.05.02 |
Tacalcitol Curatoderm® |
Lotion
Ointment
To be commenced on advice of dermatology only
|
08.02.02 |
Tacrolimus |
Capsules
Granules
Modified-release capsules
Concentrate for intravenous infusion
Prescribe by brand. Do not switch between brands.
There are 3 different oral formulations of tacrolimus:
Adoport®, Prograf®, Capexion®, Tacni®, and Vivadex® are immediate-release capsules that are taken twice daily, once in the morning and once in the evening;
Modigraf® granules are used to prepare an immediate-release oral suspension which is taken twice daily, once in the morning and once in the evening;
Advagraf® is a prolonged-release capsule that is taken once daily, in the morning. |
13.05.03 |
Tacrolimus Protopic® |
0.03% Ointment
0.1% Ointment
Consultant Dermatologist only
|
01.05.03 |
Tafacitinib Xeljanz® |
Tablets
As per NICE TA547 following MDT discussion |
08.03.04.01 |
Tamoxifen |
Tablets
|
07.04.01 |
Tamsulosin |
Capsules |
04.07.02 |
Tapentadol Palexia® |
Prolonged-release tablets
Tablets
Oral solution
- Third or fourth line option in those patients who have failed other therapies and are intolerant to oxycodone.
- To be prescribed or initiated under the advice of a specialist in pain management only.
Use of this agent should be restricted to those patients requiring treatment of severe chronic pain which CANNNOT be managed with more established opioid therapies.
|
05.01.07 |
Teicoplanin |
Injection |
04.01.01 |
Temazepam |
Tablets
Oral solution |
15.01.04.01 |
Temazepam |
|
05.01.01.02 |
Temocillin Negaban® |
Intravenous injection
For use in hospital-acquired UTIs in paediatrics - see policy
Restricted in adults - contact Microbiology for advice
|
02.10.02 |
Tenecteplase Metalyse® |
Injection |
05.03.01 |
Tenofovir 245mg, Efavirenz 600mg and Emtricitabine 200mg Atripla® |
|
05.03.01 |
Tenofovir alafenamide and Emtricitabine Descovy® |
Requires MDT discussion with ID team
|
05.03.01 |
Tenofovir alafenamide, Emtricitabine and Rilpivirine Odefsey® |
Tablet
Requires MDT discussion with ID team |
05.03.01 |
Tenofovir alafenamide, Emtricitabine, Elvitegravir and Cobicistat Genvoya® |
Tablet
Requires MDT discussion with ID team |
05.03.01 |
Tenofovir and Emtricitabine Truvada® |
|
05.03.03.01 |
Tenofovir Disoproxil Viread® |
|
05.03.01 |
Tenofovir Disproxil Viread® |
|
05.03.01 |
Tenofovir, cobicistat, elvitegravir & emtricitabine Stribild® |
Tablets
Requires MDT discussion with ID team |
05.02.05 |
Terbinafine |
Tablets
Dermatology only |
13.10.02 |
Terbinafine 1% cream |
Cream |
03.01.01.01 |
Terbutaline |
Dry powder inhaler (DPI)(Bricanyl® Turbohaler) |
03.01.01.01 |
Terbutaline |
Inhaler (see separate entry)
Nebuliser solution 5mg/2ml (Respules®) |
07.01.03 |
Terbutaline |
Injection |
06.06.01 |
Teriparatide Forsteo® |
Injection
2nd line treatment for severe osteoporosis in accordance with NICE guidance. For specialist use only
PbR excluded - commissioned by CCG |
06.05.02 |
Terlipressin Glypressin® |
Injection |
06.04.02 |
Testosterone enantate |
IM injection |
06.04.02 |
Testosterone gel Testogel® |
Gel |
06.04.02 |
Testosterone gel Tostran® |
Gel |
06.04.02 |
Testosterone implant |
Implant |
06.04.02 |
Testosterone oral Restandol Testocaps® |
Capsules |
06.04.02 |
Testosterone undecanoate |
IM injection |
14.05.02 |
Tetanus immunoglobulin |
Treatment of clinical tetanus: IV tetanus immunoglobulin no longer available - use IV human normal immunoglobulin (eg: Octagam® 10%)
Prophylaxis of tetanus-prone wounds: There are intermittent supply problems with IM tetanus immunoglobulin - use Subgam® human normal immunoglobulin SC/IM
See Public Health England (PHE) Guidance for full details
|
04.09.03 |
Tetrabenazine |
Tablets |
11.07 |
Tetracaine Hydrochloride Minims® Amethocaine Hydrochloride |
Single-use eye drops |
06.05.01 |
Tetracosactide Synacthen® |
250 microgram/ml injection (for short 30-minute test)
1mg/ml depot injection (for 5-hour test) |
05.01.03 |
Tetracycline |
Tablets |
05.01.10 |
Thalidomide |
Tablets
Approved for use by ID physicians only for patients who have steroid dependent Immune Reconsitution Syndrome (IRIS) secondary to HIV related opportunistic infection or meningeal tuberculosis in a non-HIV patient. unlicensed use |
08.02.04 |
Thalidomide Thalidomide Celgene® |
Capsules |
03.01.03 |
Theophylline |
Modified release tablets (Nuelin SA®, Uniphyllin Continus®) Modified release capsules (Slo-Phyllin®)
Specify brand when prescribing.
|
09.06.02 |
Thiamine |
Tablets |
05.01.09 |
Thioacetazone |
unlicensed
Can only be prescribed following discussion with an ID physician
|
15.01.01 |
Thiopental |
|
24.03 |
Thiotepa IV Infusion |
|
05.05.07 |
TIABENDAZOLE 500mg tabs |
Tablet
unlicensed |
04.08.01 |
Tiagabine |
Tablets
|
06.04.01.01 |
Tibolone Livial® |
Tablets |
02.09 |
Ticagrelor Brilique® |
Tablets
See information above.
Only to be prescribed on advice of cardiology |
05.01.01.04 |
Ticarcillin with Clavulanic Acid Timentin® |
Injection |
14.04 |
Tick-borne encephalitis vaccine |
NMGH Travel Clinic only |
05.01.03 |
Tigecycline |
Intravenous Infusion
Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician |
11.06 |
Timolol |
Eye drops
Unit dose eye drops
Long acting gel drops (Timolol LA®)
|
05.01.11 |
Tinidazole Fasigyn® |
Tablets |
05.04.02 |
Tinidazole |
See section 5.1.11 |
03.01.02 |
Tiotropium Spiriva® |
Respimat® inhaler 2.5 micrograms/dose.
The Spiriva Respimat device should be used with caution in patients with known cardiac rhythm disorders - see SPC |
03.01.04 |
Tiotropium / Olodaterol Spiolto® Respimat |
Metered dose inhaler Combination LABA/LAMA inhaler |
05.03.01 |
Tipranavir Aptivus® |
|
02.09 |
Tirofiban Aggrastat® |
Concentrate for infusion |
10.02.02 |
Tizanidine |
Tablets |
05.01.04 |
Tobramycin |
Injection
Dry powder inhaler ("'Podhaler'")
Nebuliser solution
Can only be prescribed for intravenous use following discussion with the Consultant Microbiologist or ID Physician
Injection solution can be nebulised in non-CF bronchiectasis; at the request of a Consultant Respiratory Physician only
|
24.01 |
Tobramycin IV infusion |
240mg ECLIPSE pump |
10.01.03 |
Tocilizumab |
Intravenous preparation ONLY
(Subcutaneous preparation is currently non-formulary) |
24.03 |
Tocilizumab IV Infusion |
|
10.01.03 |
Tofacitinib Xeljanz |
Tablets |
07.04.02 |
Tolterodine |
Tablets
M/R capsules |
06.05.02 |
Tolvaptan Samsca® |
Tablets
Endocrinologists only
|
04.07.04.02 |
Topiramate |
Tablets
Sprinkle® capsules
Topiramate hard capsules are expensive and should not be prescribed. For those patients unable to swallow topiramate tablets “sprinkle capsules” may be considered |
04.08.01 |
Topiramate |
Tablets
Sprinkle® capsules
Topiramate hard capsules are expensive and should not be prescribed. For those patients unable to swallow topiramate tablets “sprinkle capsules” may be considered |
02.02.02 |
Torasemide |
Tablets |
06.01.01.02 |
Toujeo® Insulin Glargine 300units/mL |
1.5ml prefilled disposable pen (Solostar®)
**HIGH-STRENGTH INSULIN PRODUCT** See guidance below
Only to be used in line with GMMMMG recommendations
|
04.07.02 |
Tramadol |
Capsules
Soluble tablets
M/R tablets or capsules
Injection |
02.11 |
Tranexamic Acid |
Tablets
Injection |
12.03.04 |
Tranexamic Acid Mouthwash |
unlicensed |
10.03.02 |
Transvasin |
Heat rub cream |
04.03.02 |
Tranylcypromine |
|
11.06 |
Travoprost Travatan® |
Eye drops
Does not contain benzalkonium chloride as the preservative and therefore may be used in patients where a known allergy to benzalkonium chloride exists.
|
11.06 |
Travoprost with Timolol DuoTrav® |
Eye drops
Does not contain benzalkonium chloride as the preservative and therefore may be used in patients where a known allergy to benzalkonium chloride exists.
Combination products are licensed for once daily use where prostaglandin analogue alone is not adequate. Only use where patient has difficulty with compliance/administration.
|
04.03.01 |
Trazodone |
Capsules
Tablets
Liquid |
06.01.01.02 |
Tresiba® Insulin degludec |
3ml cartridges (via Novo Nordisk® devices)
3ml pre-filled disposable pen (Flextouch®)
**Only the 100units/mL strength has been approved by the Division of Medicine. Use of the 200units/ml strength requires named-patient approval from Medical D&T Committee Chair** |
06.03.02 |
Triamcinolone Kenalog® |
Injection |
10.01.02.02 |
Triamcinolone Acetonide |
Injection |
13.04 |
Triamcinolone Acetonide 0.1% with Chlortetracycline Hydrochloride 3% Aureocort® |
Ointment |
13.07 |
Trichloroacetic Acid |
Solution |
13.11.05 |
Triclosan 2% Aquasept® |
Usage has been replaced by Hibiscrub |
04.02.01 |
Trifluoperazine |
Tablets
Oral solution 5mg/5mL
Syrup 1mg/5mL |
04.09.02 |
Trihexyphenidyl |
Tablets
Syrup |
12.01.01 |
Trimacinolone, neomycin, gramidicin and nystatin ointment Otocomb Otic® |
|
05.01.08 |
Trimethoprim |
Tablets
Oral Suspension
|
05.01.13 |
Trimethoprim |
See section 5.1.8. |
07.03.01 |
TriNovum® Ethinylestradiol / norethisterone phased pill |
Tri-phasic preparation |
01.03.03 |
Tripotassium Dicitratobismuthate De-Noltab® |
H.pylori eradication only |
08.03.04.02 |
Triptorelin SR Decapeptyl® SR |
|
11.05 |
Tropicamide Mydriacyl® |
0.5% and 1% Eye drops
0.5% and 1% single-use eye drops (Minims®)
|
07.04.02 |
Trospium |
Tablets
M/R capsules |
04.03.04 |
Tryptophan |
|
09.04.02 |
Two Cal |
|
06.04.01.02 |
Ulipristal Esmya® |
Tablets |
07.03.05 |
Ulipristal EllaOne® |
|
03.01.02 |
Umeclidinium Incruse Ellipta |
|
03.01.04 |
Umeclidinium / Vilanterol Anoro® Ellipta |
Combination LABA/LAMA inhaler |
13.02.01 |
Unguentum M® |
Cream
Dermatology only |
13.11.02 |
Unisept® Chlorhexidine Gluconate 0.05% |
Sachets |
02.10.02 |
Urokinase |
Injection |
01.09.01 |
Ursodeoxycholic acid |
Capsules
Suspension |
10.01.03 |
Ustekinumab |
Subcutaneous Injection
Approved for use as per NICE TA340, i.e.:
Ustekinumab is recommended as an option, alone or in combination with methotrexate, for treating active psoriatic arthritis in adults only when: • treatment with TNF alpha inhibitors is contraindicated but would otherwise be considered (as described in NICE guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis and golimumab for the treatment of psoriatic arthritis) • or the person has had treatment with 1 or more TNF–alpha inhibitors.
Ustekinumab is recommended only if the company provides the 90mg dose of ustekinumab for people who weigh more than 100 kg at the same cost as the 45mg dose, as agreed in the patient access scheme. |
13.05.03 |
Ustekinumab |
NICE and GMMMG recommend ustekinumab as an option, alone or in combination with methotrexate, for treating active psoriatic arthritis in adults only when:
• treatment with TNF alpha inhibitors is contraindicated but would otherwise be considered
• or the person has had treatment with 1 or more TNF–alpha inhibitors.
Consideration should be given to discontinuing treatment in patients who have shown no response up to 28 weeks of treatment.
Available via Patient Access Scheme: please contact pharmacy for details
|
13.08.01 |
Uvistat® |
Cream
Ultrablock Cream
Preparations with an SPF less than 30 should not be prescribed. |
05.03.02.01 |
Valaciclovir Valtrex® |
Tablets
Can only be prescribed on advice of ID physician or virologist |
05.03.02.02 |
Valganciclovir Valcyte® |
|
04.02.03 |
Valproic Acid Depakote® |
Tablets |
02.05.05.02 |
Valsartan |
Tablets
GMMMG endorse use in post-myocardial infarction. |
02.05.05.02 |
Valsartan / Sacubitril Entresto® |
Tablets
To be initiated by Heart Failure team |
05.01.07 |
Vancomycin |
Capsules
Injection
Green1 for severe or recurrent C.diff only. To be used on advice of microbiology for other indications
|
24.01 |
Vancomycin IV Infusion |
500mg
750mg
1000mg
1250mg
1500mg
2000mg |
24.01 |
Vancomycin IV Syringe for neonatal use |
40mg in 8mL sodium chloride 0.9%
80mg in 16mL sodium chloride 0.9% |
04.10.02 |
Varenicline Champix® |
|
14.05.02 |
Varicella-Zoster immunoglobulin |
Medical team to contact Clinical Virology at Central Manchester Foundation Trust (0161 276 8853) |
14.04 |
Varicella-zoster vaccine Varivax® |
|
06.05.02 |
Vasopressin Pitressin® |
Injection |
15.01.05 |
Vecuronium Bromide Norcuron® |
|
01.05.03 |
Vedolizumab Entyvio® |
|
24.03 |
Vedolizumab IV Infusion |
|
08.01.05 |
Venetoclax Venclyxto® |
|
04.03.04 |
Venlafaxine |
Tablets
M/R tablets or capsules |
02.06.02 |
Verapamil |
Standard tablets
Modified release tablets
Modified release capsules
Injection
|
04.08.01 |
Vigabatrin |
Tablets
Powder sachets |
24.03 |
Vinblastine IV Infusion |
|
24.03 |
Vincristine IV Infusion |
|
18 |
Viper Venom antisurem |
|
09.04.02 |
Vital 1.5kcal |
|
09.04 |
Vital 1.5kcal 200ML |
|
09.06.02 |
Vitamin B Tablets (Compound) |
Tablets |
09.06.02 |
Vitamin B Tablets, Compound Strong |
Tablets
For the prevention of re-feeding syndrome only |
09.06.01 |
Vitamins A and D |
Capsules
unlicensed |
05.02.01 |
Voriconazole Vfend® |
Tablets
Oral Suspension
Intravenous Infusion
Can only be prescribed following discussion with the Consultant Microbiologist, ID Physician or Haematologist |
11.03.02 |
Voriconazole |
1% eye drops
Ophthalmic consultant initiation only |
04.03.04 |
Vortioxetine Brintellix® |
|
02.08.02 |
Warfarin |
Tablets |
02.08.02 |
Warfarin |
Tablets |
13.02.01 |
White Soft Paraffin BP |
Ointment |
11.08.01 |
White soft paraffin, white mineral oil, anolin alcohols lubricating eye ointment Xailin Night® |
N.B. may be applied as often as required and is particularly suitable for overnight use. |
12.02.02 |
Xylometazoline Otrivine® |
Nasal drops |
01.07.02 |
Xyloproct® |
Ointment |
14.04 |
Yellow fever vaccine (Live) |
NMGH Travel Clinic only |
13.02.01 |
Yellow Soft Parrafin BP |
Jelly |
05.03.04 |
Zanamivir inhalation Relenza® |
Dry powder for inhalation |
07.03.02 |
Zelleta® Desogestrel 75mcg |
Tablets |
13.02.01 |
Zerobase® |
Cream |
05.03.01 |
Zidovudine Retrovir® |
Capsules
Oral Solution
Injection |
05.03.01 |
Zidovudine and Lamivudine Combivir® |
|
13.05.02 |
Zinc and Salicylic Acid Paste BP Lassar's Paste |
Paste
unlicensed |
09.05.04 |
Zinc Sulphate Solvazinc® |
Effervescent tablets |
06.06.02 |
Zoledronic Acid Zometa® |
Intravenous infusion
For reduction of bone damage in advanced malignancies involving bone, and hypercalcaemia of malignancy |
06.06.02 |
Zoledronic Acid Aclasta® |
Intravenous infusion
For:
Paget's disease of bone,
Postmenopausal osteoporosis ( See GMMMG NTS recommendation),
and osteoporosis in men |
04.01.01 |
Zolpidem |
Tablets |
04.08.01 |
Zonisamide |
Capsules |
04.01.01 |
Zopiclone |
Tablets |
04.02.01 |
Zuclopenthixol |
Tablets |
04.02.01 |
Zuclopenthixol Acetate injection Clopixol Acuphase® |
|
04.02.02 |
Zuclopenthixol Decanoate Clopixol® |
|